

# BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [info.bmjopen@bmj.com](mailto:info.bmjopen@bmj.com)

# BMJ Open

## How European primary care practitioners think the timeliness of cancer diagnosis can be improved – a thematic analysis

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-030169
Article Type:	Research
Date Submitted by the Author:	04-Mar-2019
Complete List of Authors:	<p>Harris, Michael; University of Bath, Department for Health; Universität Bern, Berner Institut für Hausarztmedizin (BIHAM)</p> <p>Thulesius, Hans; Lund University, Department of Clinical Sciences; Department of Research and Development</p> <p>Neves, Ana Luísa; Imperial College London, Institute of Global Health Innovation; University of Porto, CINTESIS (Centre for Health Technology and Services Research) and MEDCIDS (Department of Community Medicine, Information and Health Decision Sciences), Faculty of Medicine</p> <p>Harker, Sophie; University of Bath, Department for Health</p> <p>Koskela, Tuomas; Tampere University, Faculty of Medicine and Health Technology</p> <p>Petek, Davorina; Univerza v Ljubljani, Department of Family Medicine</p> <p>Hoffman, Robert; Tel Aviv University, Department of Family Medicine</p> <p>Brekke, Mette; University of Oslo, Department of General Practice and General Practice Research Unit</p> <p>Buczowski, Krzysztof; Nicolaus Copernicus University, Department of Family Medicine</p> <p>Buono, Nicola; SNAMID, Family medicine</p> <p>Costiug, Emiliana; Universitatea de Medicina si Farmacie Iuliu Hatieganu, Family Medicine Department</p> <p>Dinant, Geert-Jan; Maastricht University, Dept of General Practice</p> <p>Foreva, Gergana; Medical Center BROD</p> <p>Jakob, Eva; Centro de Saúde Sarria, Primary Health Centre</p> <p>Marzo, Mercè; Unitat de Suport a la Recerca Costa de Ponent, IDIAP</p> <p>Jordi Gol,</p> <p>Murchie, Peter; University of Aberdeen, Division of Applied Health Science</p> <p>Sawicka-Powierza, Jolanta; Uniwersytet Medyczny w Białymstoku, Department of Family Medicine</p> <p>Schneider, Antonius; Technical University Munich, Institute of General Practice</p> <p>Smyrnakis, Emmanouil; Aristotle University of Thessaloniki , Laboratory of Primary Health Care, General Practice and Health Services Research</p> <p>Streit, Sven; Universität Bern, Berner Institut für Hausarztmedizin (BIHAM)</p> <p>Taylor, Gordon; University of Exeter, College of Medicine and Health</p> <p>Vedsted, Peter; Research Unit for General Practice, University of Aarhus</p> <p>Weltermann, Birgitta; University of Bonn, Institut für Hausarztmedizin</p> <p>Esteva, Magdalena; Gerencia Atencio Primaria de Mallorca, Unidad de</p>

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

	Investigación
Keywords:	Delivery of Health Care, Primary Health Care, General Practitioners, Cancer, Diagnosis, Consultation and Referral



# How European primary care practitioners think the timeliness of cancer diagnosis can be improved – a thematic analysis

Michael Harris <sup>1,2</sup> (corresponding author), michaelharris681@btinternet.com

Hans Thulesius <sup>3,4</sup>, hansthulesius@gmail.com

Ana Luísa Neves <sup>5,6</sup>, ana.luisa.neves@gmail.com

Sophie Harker <sup>1</sup>, sophie.888@btinternet.com

Tuomas Koskela <sup>7</sup>, tuomas.koskela@tuni.fi

Davorina Petek <sup>8</sup>, davorina.petek@gmail.com

Robert D. Hoffman <sup>9</sup>, hofman\_r@mac.org.il

Mette Brekke <sup>10</sup>, mette.brekke@medisin.uio.no

Krzysztof Buczkowski <sup>11</sup>, buczkowskik@cm.umk.pl

Nicola Buono <sup>12</sup>, buono.nicola2@gmail.com

Emiliana Costiug <sup>13</sup>, dr.costiug@gmail.com

Geert-Jan Dinant <sup>14</sup>, geertjan.dinant@maastrichtuniversity.nl

Gergana Foreva <sup>15</sup>, gerganaforeva@gmail.com

Eva Jakob <sup>16</sup>, eva.jacob.gonzalez@sergas.es

Mercè Marzo-Castillejo <sup>17</sup>, mmarzoc@gencat.cat

Peter Murchie <sup>18</sup>, p.murchie@abdn.ac.uk

Jolanta Sawicka-Powierza <sup>19</sup>, jolasawicka@gmail.com

Antonius Schneider <sup>20</sup>, antonius.schneider@tum.de

Emmanouil Smyrnakis <sup>21</sup>, smyrnak@auth.gr

1 Sven Streit <sup>2</sup>, sven.streit@biham.unibe.ch

2 Gordon Taylor <sup>22</sup>, g.j.taylor@exeter.ac.uk

3  
4  
5 Peter Vedsted <sup>23</sup>, p.vedsted@alm.au.dk

6  
7  
8 Birgitta Weltermann <sup>24</sup>, birgitta.weltermann@ukbonn.de

9  
10  
11 Magdalena Esteva <sup>25</sup>, mesteva@ibsalut.caib.es

12  
13  
14  
15  
16  
17 <sup>1</sup> Department for Health, University of Bath, Claverton Down, Bath BA2 7AY, UK; telephone:  
18 +44 1761 241366; fax: none.

19  
20  
21 <sup>2</sup> Institute of Primary Health Care Bern (BIHAM), University of Bern, Bern, Switzerland

22  
23  
24 <sup>3</sup> Department of Clinical Sciences, Lund University, Malmö, Sweden

25  
26  
27 <sup>4</sup> Department of Research and Development, Region Kronoberg, Sweden

28  
29  
30 <sup>5</sup> Institute of Global Health Innovation, Imperial College, London, UK.

31  
32  
33 <sup>6</sup> CINTESIS (Centre for Health Technology and Services Research) and MEDCIDS (Department  
34 of Community Medicine, Information and Health Decision Sciences), Faculty of Medicine,  
35 University of Porto, Porto, Portugal

36  
37  
38 <sup>7</sup> Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.

39  
40  
41 <sup>8</sup> Department of Family Medicine, University of Ljubljana, Ljubljana, Slovenia.

42  
43  
44 <sup>9</sup> Department of Family Medicine, Tel Aviv University, Tel Aviv, Israel.

45  
46  
47  
48 <sup>10</sup> Department of General Practice and General Practice Research Unit, University of Oslo, Oslo,  
49 Norway.

50  
51  
52 <sup>11</sup> Department of Family Medicine, Nicolaus Copernicus University, Toruń, Poland.

53  
54  
55  
56  
57 <sup>12</sup> Department of General Practice, National Society of Medical Education in General Practice  
58 (SNaMID), Caserta, Italy.

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47
- <sup>13</sup> Family Medicine Department, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania.
- <sup>14</sup> Department of General Practice, Maastricht University, Maastricht, Netherlands.
- <sup>15</sup> Medical Center BROD, Plovdiv, Bulgaria
- <sup>16</sup> Primary Health Centre, Centro de Saúde Sarria, Sarria, Lugo, Spain.
- <sup>17</sup> Unitat de Suport a la Recerca, IDIAP Jordi Gol, Institut Català de la Salut, Barcelona, Spain.
- <sup>18</sup> Division of Applied Health Sciences - Academic Primary Care, University of Aberdeen, Aberdeen, UK.
- <sup>19</sup> Department of Family Medicine, Medical University of Bialystok, Bialystok, Poland.
- <sup>20</sup> Institut für Allgemeinmedizin, Technische Universität München, Munich, Germany.
- <sup>21</sup> Laboratory of Primary Health Care, General Practice and Health Services Research, Aristotle University of Thessaloniki, Thessaloniki, Greece.
- <sup>22</sup> College of Medicine and Health, University of Exeter, Exeter, UK.
- <sup>23</sup> The Research Unit for General Practice, Aarhus University, Aarhus, Denmark.
- <sup>24</sup> Institut für Hausarztmedizin, University of Bonn, Bonn, Germany.
- <sup>25</sup> Research Unit, Majorca Primary Health Care Department, Balearic Islands Health Research Institute (IdISBa), Preventive Activities and Health Promotion Network, Carlos III Institute of Health (RedIAPP-RETICS), Palma, Spain.

48  
49

### Keywords

50  
51  
52  
53  
54  
55

Delivery of Health Care; Primary Health Care; General Practitioners; Cancer; Diagnosis; Consultation and Referral.

56  
57

### Word count

58  
59  
60

2,920 (excluding data/quotes)

## Abstract

### Background

National European cancer survival rates vary widely. Prolonged diagnostic intervals are thought to be a key factor in explaining these variations. Primary Care Practitioners (PCPs) frequently play a crucial role during initial cancer diagnosis; their knowledge could be used to improve the planning of more effective approaches to earlier cancer diagnosis.

### Objectives

This study sought the views of PCPs from across Europe on how they thought the timeliness of cancer diagnosis could be improved.

### Design

In an online survey, an open-ended question asked PCPs how they thought the speed of diagnosis of cancer in primary care could be improved. Thematic analysis was used to analyse the data.

### Setting

A primary care study, with participating centres in twenty European countries.

### Participants

A total of 1,352 PCPs answered the survey question, with a median of 48 per country.

### Results

The main themes identified were: patient-related factors, including health education; care provider-related factors, including continuing medical education; improving communication and inter-professional partnership, particularly between primary and secondary care; factors relating to health system organization and policies, including improving access to health care;

1  
2 easier primary care access to diagnostic tests; and use of information technology. Re-  
3 allocation of funding to support timely diagnosis was seen as an issue affecting all of these.  
4

## 5 **Conclusions**

6  
7  
8 To achieve more timely cancer diagnosis, health systems need to facilitate earlier patient  
9 presentation through education and better access to care, have well-educated clinicians with  
10 good access to investigations and better information technology, and adequate primary care  
11 cancer diagnostic pathway funding.  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



## Article Summary

### Strengths and limitations of this study

- This this is the first trans-European study to explore PCPs' perceptions of how timeliness of cancer diagnosis can be improved.
- Variation in geography, health systems and levels of healthcare spending was provided recruiting PCPs from 20 European countries, four countries from each of the Northern, Southern, Eastern, Western and Central European geographical areas.
- The survey had only one question that related directly to our research question.
- Neither patients, secondary care nor other primary care health professionals were included in the survey, and these groups may have had other insights to offer.

## Introduction

1  
2  
3 Cancer survival rates vary widely in Europe <sup>1</sup>, leading to considerable additional mortality in  
4  
5 some countries. Data from the European Cancer Registry-based Study on Survival and Care of  
6  
7 Cancer Patients (EUROCARE-5) show that the national 1-year relative survival rates for all  
8  
9 cancer sites vary from 58.2% to 81.1% <sup>2</sup>. Poorer 1-year relative survival is thought to be  
10  
11 indicative of diagnostic delay <sup>3 4</sup> and more advanced disease at diagnosis <sup>5 6</sup>, although it can be  
12  
13 affected by differences in registration, as well as overdiagnosis and lead-time biases <sup>7 8</sup>. There  
14  
15 may also be geographical differences in incidence of cancers that have a poorer prognosis <sup>9</sup>, as  
16  
17 well as national variations in access to effective cancer treatment <sup>10</sup>, and in levels of poverty,  
18  
19 which in itself has been linked with more advanced disease stage at diagnosis <sup>11-13</sup>. More  
20  
21 advanced cancers are more difficult to treat successfully <sup>14</sup> and, for many cancers, the stage of  
22  
23 disease at diagnosis is related to survival <sup>15 16</sup>. There is considerable evidence that longer time  
24  
25 to diagnosis and treatment has an adverse impact on cancer mortality <sup>17-23</sup>. Timely care also  
26  
27 adds to patients' quality of life and emotional well-being <sup>24</sup>. In addition, patients' descriptions  
28  
29 of the quality of their care are closely related to the speed of their diagnosis and treatment;  
30  
31 this is because they are concerned that longer waits might allow time for their cancers to  
32  
33 grow <sup>25</sup>.

34  
35  
36  
37  
38  
39  
40  
41 Timely diagnosis of cancer has therefore been an important aim of healthcare providers  
42  
43 across Europe <sup>25</sup>. However, the challenge in deciding where and how to achieve this is  
44  
45 substantial <sup>26</sup>. In countries where a comparatively low 1-year cancer survival suggests that  
46  
47 late diagnosis may be a major factor, it is uncertain whether this is due to patients presenting  
48  
49 later to health-care, whether they are not being referred quickly enough by those in primary  
50  
51 care, or whether they are not being investigated and managed efficiently in secondary care <sup>14</sup>.  
52  
53 This may be a particular problem where patients with cancer present without red-flag  
54  
55 symptoms, as how their primary care practitioners (PCPs) act depends on how their health  
56  
57 systems are organised <sup>27</sup>.  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Doctors and their patients recognise that general practitioners (GPs) and other PCPs have a key role in cancer detection <sup>28-30</sup>. It has been suggested that PCPs' knowledge of their patient populations can be used to improve health service design <sup>31</sup> and the planning for more effective approaches to earlier cancer recognition and referral <sup>32</sup>. There has been a call for research in this field <sup>15</sup>; although PCPs' experience of their own health systems could potentially help to improve the planning of more effective approaches to earlier cancer recognition and referral, their perceptions have not been previously evaluated.

The Örenäs Research Group, a European group of primary care researchers that studies the primary care factors that relate to cancer survival, therefore decided to elicit the views of GPs and other PCPs from across Europe on how they thought the timeliness of cancer diagnosis could be improved.

## Methods and design

### Design

Between November 2015 and December 2016, we performed an online survey of PCPs in 20 European countries. The methodology of the study is described in our published protocol paper <sup>33</sup>.

### Development of the questionnaire

After a literature review, Örenäs Research Group investigators developed a questionnaire designed to elicit PCPs' referral decisions on patients that could have cancer, and their degree of agreement with items relating to health system aspects that could affect their decision to refer patients with potential cancer symptoms for further investigation. The final, open-ended question asked: 'How do you think the speed of diagnosis of cancer in primary care could be improved?' The answers to this question are used in this analysis.

The questionnaire was piloted twice by PCPs in 16 Örenäs Research Group centres. No changes were made to the final, open-ended question after either of the piloting stages. Örenäs Research Group leads arranged for translations of the questionnaire into their local languages where these were not English, a total of 19 translations from the original English. Translation, validation by back-translation to assess semantic and conceptual equivalence, and cultural adaptation <sup>34</sup> of the survey were done in a standardised way <sup>35</sup> and are described elsewhere <sup>36</sup>. The questionnaires were put online using SurveyMonkey (SurveyMonkey, California, USA).

### Participants and recruitment

The study was conducted in 25 Örenäs Research Group centres in 20 countries across Europe: Bulgaria, Croatia, Denmark, England, Finland, France, Germany, Greece, Israel, Italy, Netherlands, Norway, Poland, Portugal, Romania, Scotland, Slovenia, Spain, Sweden and

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Switzerland. Local study leads were asked to either gain ethical approval or obtain a statement that formal ethical approval was not needed in their jurisdiction (see supplementary file).

Criterion sampling was used <sup>37</sup>, with subjects being eligible for the survey if they were doctors working mainly in primary care. These doctors, referred to collectively here as 'Primary Care Practitioners', consisted of GPs as well as other doctors who had specialist training but worked in the community and could be accessed directly by patients without referral.

Each Örenäs Research Group local lead was asked to email a survey invitation to the PCPs in their local health district, and to recruit at least 50 participants. This allowed recruitment of a varied sample with regards to gender, years since graduation, site of practice (urban, rural, remote), and size of practice. Consent was implied by agreeing to take part in the survey.

### **Data analysis**

Local Örenäs Research Group leads translated the responses from their own languages into English and sent them to MH, who asked them for more information where the translation or context was unclear.

We used inductive thematic analysis <sup>38</sup>, an approach in which codes and themes are suggested by the data rather than by a theoretical framework. The phases of analysis included coding, followed by the identification and clustering of themes and sub-themes, and the production of a descriptive thematic summary. Two researchers (MH and SH) independently coded the data from three countries and compared their analyses for inconsistencies and agreement. MH then coded the data from the other countries. Team members from seven participating countries (ME, MH, RH, TK, ALN, DP, HT, all PCPs) then independently considered themes and sub-themes, discussed these and came to a consensus over the course of two meetings. The themes and sub-themes were grouped to construct an interpretative narrative across the dataset and depicted diagrammatically. Apart from SH, a Masters psychology student, all

1 authors involved in the coding and thematic analysis were experienced general practitioners  
2 who were also active in primary care research.  
3

## 4 **Patient and public involvement**

5  
6  
7 There was no patient or public involvement in this study.  
8  
9

## 10 **Results**

11  
12  
13  
14  
15 A total of 1,833 PCPs completed the full questionnaire, with a median response rate per  
16  
17 country of 24.8% (range 7.1% to 65.6%). All participating centres received at least 50  
18  
19 responses, with a median of 61 PCPs per country. In all, 1,352 PCPs (73.8% of completers)  
20  
21 gave an answer to the final, open-ended survey question on “how could the speed of diagnosis  
22  
23 of cancer in primary care could be improved?”, with a median of 48 per country (Table 1). The  
24  
25 demographic distributions of the PCPs answering this question are shown in Table 2. Towards  
26  
27 the end of the analysis, no new themes emerged.  
28  
29

30  
31 We identified four main themes organising the content of the responses to the question:  
32  
33 patient-related factors, care provider-related features, improving communication and inter-  
34  
35 professional partnership, and aspects of health system organisation and health policies. Two  
36  
37 structural facets transcended the four themes: accessing diagnostic tests and using  
38  
39 information technology. The issue of allocating funding to support timely diagnosis fed into all  
40  
41 the other themes. The themes are shown diagrammatically in Figure 1. Themes and  
42  
43 subthemes are described below, with participant quotations identified by country and a  
44  
45 participant number.  
46  
47  
48  
49

50  
51 **(Place Figure 1 here)**  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Patient-related factors**

1  
2 This theme included ideas on education and training to improve patient knowledge. Many  
3  
4  
5 PCPs advocated the use of health education and media campaigns to improve patient  
6  
7 awareness of alarm symptoms and signs:  
8  
9

10 'By giving patients better information about when to go to a doctor - reduce patient  
11  
12 delay.' (Denmark, PCP69)  
13

14  
15 'Improve health literacy of patients regarding the detection of early symptoms that  
16  
17 might indicate oncological disease.' (Portugal, PCP37)  
18

19  
20 Targeting advice on cancer risks was also considered important:  
21  
22

23 'Informing patients about cancer risks related to their age groups.' (Italy, PCP28)  
24  
25

26 However, public health messages could be seen as unworkable:  
27  
28

29 'Stop public campaigns telling everyone with a particular symptom they need seen eg  
30  
31 chest X-ray after 3 weeks of cough – inappropriately blocking the service.' (Scotland,  
32  
33 PCP16)  
34  
35

**Care provider-related factors**

36  
37  
38  
39 PCPs had suggestions on how to improve their own knowledge and that of other caregivers,  
40  
41 by both increasing the amount of the training and improving the teaching content. Improving  
42  
43 the training of PCPs and other health care professionals was considered by many respondents  
44  
45 to be important:  
46  
47

48  
49 'By educating health care professionals. When to suspect and when to do further tests?'  
50  
51 (Finland, PCP33)  
52  
53

54  
55 'CME [continuing medical education] on early signs and up-to-date investigation  
56  
57 processes.' (Sweden, PCP52)  
58  
59

60 Alertness in their role was also considered key:

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

'Often the presence of alarm signs is too late ... Be alert and listen to the patients.'

(Spain, PCP46)

Primary care doctors also need to be aware of the relevant clinical pathways:

'Training of GPs ... taking into account the entire pathway from symptom to diagnosis.'

(Poland, PCP17)

PCPs thought it important that cancer screening and referral guidelines should be clear, and that they themselves should be involved in designing them.

'Clear guidelines regarding cancer alarm signs and referral indications.' (Finland, PCP37)

'GPs who design guidelines together with specialists.' (Sweden, PCP21)

### **Improving communication and inter-professional partnership**

Patient-PCP communication improvements and enhancements to inter-professional partnerships were frequently suggested by the PCP respondents. Improving communication with patients was considered important, though this implied having longer consultations:

'GPs should pay more attention when they speak to patients.' (Italy, PCP26)

'Longer consultations to allow more thorough assessment without pressure of time.'  
(Scotland, PCP5)

Improving the interaction within the practice team could also be helpful:

'Discussion in the team about recent referrals so the team benchmarks itself.' (England, PCP22)

'A lot can be learnt from colleagues' experiences of missed diagnoses.' (Netherlands, PCP40)



1  
2 Improving partnership between PCPs and other primary health care professionals, for  
3 example nurses and health-care assistants, with adequate training, was also considered  
4 important:  
5

6  
7 'Involve the nurses in gathering the patient's medical history.' (Poland, PCP20)  
8

9  
10 'Good training of health-care assistant to identify risk symptoms.' (Norway, PCP1)  
11

12  
13 Improving the relationship between primary and secondary care doctors, with easier and  
14 reliable communication between the two, was highlighted:  
15

16  
17 'Easy communication with specialists (and, in my case, preferably email contact).'  
18

19  
20 (Netherlands, PCP85)  
21

22  
23 'It is essential to establish a communication channel between primary health care and  
24 specialist health care so that critical patients would not get lost in the system.' (Croatia,  
25 PCP36)  
26  
27  
28

29  
30 Joint working with public health departments was also considered valuable:  
31

32  
33 'With the cooperation between the National Institute of Public Health and family  
34 medicine specialists, who know their patients best.' (Croatia, PCP38)  
35  
36

37  
38 Many doctors commented on the importance of continuity of care:  
39

40  
41 'Knowing your patient well. Consequently, not having three different GPs for one  
42 patient.' (Netherlands, PCP69)  
43  
44  
45

#### 46 47 **Strengthening system organisation and improving health policy** 48

49  
50 Strengthening how health systems are organised and implementing health policies that allow  
51 timely cancer diagnosis were key recommendations from many PCPs. Enhancing patient  
52 access to primary care, particularly for vulnerable or more remote groups, was considered  
53 important by some:  
54  
55  
56  
57  
58  
59  
60

1 'Shorter queues to GP appointment in order to start assessments without delay.'

2 (Finland, PCP33)

3  
4 'In some places (rural, inland) inaccessibility to MCDTs [screening examinations] can  
5 be an obstacle.' Portugal, PCP43)

6  
7  
8  
9  
10 Practical steps to improve access to secondary care were also seen as key, particularly those  
11 relating to costs to the patient:

12  
13  
14  
15 'Access to specialists must be cheaper.' (Romania, PCP99)

16  
17  
18 'Patient friendly hospital services - so that the appointments are not too stressful or  
19 expensive (travel and parking).' (England, PCP19)

20  
21  
22  
23 Many PCPs commented on the need for better working conditions, a larger workforce, a  
24 reduced workload and less bureaucracy:

25  
26  
27  
28 'A sufficient number of healthcare professionals so that there is not too much workload  
29 for a few.' (Croatia, PCP5)

30  
31  
32  
33 'Reduction of the workload at the family medicine doctor office.' (Croatia, PCP31)

34  
35  
36  
37 'By decreasing bureaucracy! So we will have more time for a real consultation!'  
38 (Romania, PCP49)

39  
40  
41 The adoption of financial incentives schemes was also suggested:

42  
43  
44  
45 'Allocating additional financial resources and stimulating the GP in this direction.'  
46 (Romania, PCP78)

47  
48  
49  
50 'Financial incentives for preventative care of most common malignant conditions.'  
51 (Bulgaria, PCP4)

52  
53  
54 PCPs felt that guidelines and protocols needed to be clear and relevant to them:

55  
56  
57  
58 'Clear guidelines regarding cancer alarm signs and referral indications.' (Finland,  
59 PCP37)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

'By developing a more specific GP protocol for the various types of cancer.'

(Netherlands, PCP51)

Fast-track systems for patients with cancer were requested by many respondents:

'Create a fast-track unit for patients with high cancer suspicion.' (Spain, PCP51)

'Preferential appointments for cases with cancer suspicion in all hospital specialities.'

(Spain, PCP6)

In countries where fast-track systems already existed, these were seen as a success:

'Cancer diagnostics have priority in the Norwegian health care system since fast track referral was introduced last year. Functions well.' (Norway, PCP5)

'I actually think that the introduction of the "2-week wait" urgent referral system has greatly improved the speed of diagnosis for those with obvious red flag symptoms.'

(England, PCP11)

Some PCPs felt that there should be more uptake of national screening programmes:

'Encourage patients to use existing prevention programmes.' (Germany, PCP7)

'All physicians should adhere to screening guidelines.' (Switzerland, PCP8)

### Accessing diagnostic tests

This theme suggesting improvements to diagnostic structures dealt mainly with easier and quicker access to testing. Easier PCP access to diagnostic testing was cited by many respondents:

'Increasing the range of diagnostics available; also making them easier to refer for.'

(Netherlands, PCP79)

'Facilitating family doctors to request tests and investigations that he/she considers necessary for the diagnosis.' (Spain, PCP39)

Many felt that they should have direct access to cancer-specific testing:

1  
2 'GPs should be able to recommend any investigation without reference to other  
3 specialist doctors.' (Romania, PCP44)  
4  
5

6  
7 'Give GPs the ability to refer patients to more diagnostic tests e.g. CT, tumour markers.'  
8  
9 (Poland, PCP26)  
10  
11

12  
13 The speed of access to diagnostic tests was also seen as key:

14  
15 'Faster access/fast track to imaging diagnostics could help us exclude a number of  
16 cases and so could relieve specialist services.' (Norway, PCP18)  
17  
18

19  
20 'Reduction of the delay in getting special tests.' (France, PCP 2)  
21  
22

23  
24 However, some PCPs were worried that the increase in investigation of patients needed to  
25 diagnose cancers earlier could also lead to overdiagnosis and overtreatment:  
26  
27

28  
29 'Cancer diagnostics are a difficult balancing act between under- and overdiagnosis.  
30 Faster cancer diagnostics will also give more overdiagnosis.' (Norway, PCP 31)  
31  
32

33  
34 'Depends on the type of cancer, but there is a trade-off between diagnosing a few cancers  
35 earlier by referring lots more patients to specialist clinics and the increased stress,  
36 anxiety, expense and risk of physical harm from unnecessary ionizing radiation and  
37 treatments.' (England, PCP 7)  
38  
39  
40  
41  
42  
43

#### 44 **Using information technology**

45  
46  
47 This theme was about using electronic information and communication to improve diagnostic  
48 capability and enhance partnership working. Some PCPs thought that more decision support  
49 aids should be included in electronic health records:  
50  
51

52  
53  
54 'Automatic decision support/diagnostic support in the GP electronic information  
55 system based on symptoms.' (Netherlands, PCP10)  
56  
57  
58  
59  
60

1 'The 29 Norwegian guidelines regarding 'fast track referral for cancer' could be  
2 included into our electronic patient files as a real decision aid with extraction of clinical  
3 information for the referral.' (Norway, PCP3)  
4  
5  
6

7 Information technology could also be used to help identify those who would benefit from  
8 screening, and provide reminders relating to individual patients where needed:  
9  
10

11 'Select specific age groups from healthcare databases and identify the individuals that  
12 haven't had the screening.' (Portugal, PCP11)  
13  
14  
15

16 'Using an automatic reminder system for cancer screening for each patient.' (Greece,  
17 PCP15)  
18  
19  
20  
21

22 Some PCPs were keen on the option to have 'virtual consultations' with specialists:  
23  
24

25 'Allow virtual consultations with specialists in specific subjects to validate malignancy  
26 diagnosis (radiologists/pulmonologists/gastroenterologists/surgeons, etc.) (Israel,  
27 PCP18)  
28  
29  
30  
31  
32

### 33 **Allocating funding to support timely diagnosis**

34

35 Adequate resources for primary care and targeted funding for investigations were frequently  
36 recommended by participants. This theme wove through the whole cancer diagnostic process.  
37  
38 An increase in primary care financing was considered to be necessary if PCPs were to improve  
39 access to care:  
40  
41  
42  
43  
44

45 'By increasing resources in primary care in order to improve the access to care.'  
46 (Finland, PCP34)  
47  
48  
49  
50

51 Adequate funds were also seen to be needed for screening and diagnostic tests:  
52  
53

54 'Increase funding of screening tests.' (Poland, PCP20)  
55  
56

57 'A higher budget for diagnostic tests, covering ... some higher costs related to the  
58 investigation and early diagnosis of cancer.' (Romania, PCP59)  
59  
60

In some countries, there was a need for an increase in the budget for diagnostic tests and referrals:

'Increase funding for cancer diagnostic tests (tumour markers, colonoscopy, gastroscopy, radiographs) - currently, the funding is insufficient.' (Poland, PCP29)

'Unlimited lab tests and unlimited referrals to specialist services if malignant conditions are suspected.' (Bulgaria, PCP11)

Funding limitations could be an issue for patients:

'Many patients refuse the investigations because of the costs (tumour markers, MRI, extra payment to the specialist doctor, ineffective collaboration between specialities).' (Romania, PCP12)

This could also affect the finances of the PCPs themselves:

'Ensure adequate financial support – at present there are penalties if the number of consultations exceeds the limit, even if the consultations are clinically indicated.' (Bulgaria, PCP25)

## Discussion

### Principal findings

In this primary care study, participants were able to use their experience situated in their own healthcare systems to provide a rich variety of suggestions for the improvements needed to allow more timely diagnosis of cancer. These covered the whole diagnostic pathway, from recommendations on how to help patients to present earlier with their symptoms, through continuing medical education that would help PCPs to recognise and act on symptoms that could be due to cancer, to improving communication and inter-professional partnership between and within primary and secondary care. Improving health system organisation and health policies is essential for achieving these goals. Facilitating patients' access to health care

was also considered important, as was enabling fast and direct PCP access to diagnostic tests.

Respondents saw funding allocation as an underlying component of most of these issues. They also identified a risk that reducing delays in cancer diagnosis in some patients could lead to overdiagnosis in others.

### **Strengths and weaknesses of the study**

To our knowledge, this is the first trans-European study to explore PCPs' perceptions of how timeliness of cancer diagnosis can be improved, offering a unique insight into the operational and administrative challenges. This could be invaluable for the evaluation and revision of current healthcare policies and practices.

Variation in geography, health systems and levels of healthcare spending was provided by having four participating countries from each of the Central, Eastern, Northern, Southern and Western European geographical areas. The sample size was large and diverse, with participants varying in terms years of clinical practice, gender, and site and size of practice. The study successfully recruited participants in countries in which PCPs are underrepresented in research.

The survey had only one, short question that related directly to our research question. However, it may be that this format prompted participants to focus on writing down only what, for them, was the most important point. Neither patients, secondary care nor other primary care health professionals were included in the survey, and these groups may have had other insights to offer. There is a risk that the translators and investigators misunderstood some of the nuances of the twenty different languages, cultures and healthcare organisations involved in this study. While themes were identified from responses from PCPs in 20 European countries, not all of the themes identified will be equally relevant to each of the participating countries.

## Comparison with other studies

1  
2  
3 Our findings map across to those of a survey of GPs in Ireland, which identified that barriers  
4  
5 to early cancer diagnosis included lack of direct GP access to diagnostic tests, difficulties with  
6  
7 referral to secondary care, poor clarity relating to cancer screening, unequal patient access to  
8  
9 secondary services, and a need for further training and guidelines<sup>39</sup>. GPs' views on the  
10  
11 importance of closer links between primary and secondary care were identified in that study,  
12  
13 and also in a United Kingdom (UK) study<sup>29</sup>. Our PCPs' call for improved patient education and  
14  
15 better access to diagnostic testing specialist care were also prioritised by GPs in another UK  
16  
17 study<sup>40</sup>. An Australian study of GPs' perceptions identified a need to reduce system barriers  
18  
19 and workforce pressures in general practice<sup>30</sup>.

20  
21  
22  
23  
24 The need for healthcare systems to support PCPs' quick and easy access to investigations has  
25  
26 been proposed before<sup>41</sup>. While investigation in primary care has been linked with later  
27  
28 referral for specialist assessment, reducing the waiting time for tests would be expected to  
29  
30 shorten the primary-care intervals associated with investigation use<sup>42</sup>. Despite this, another  
31  
32 study found that some patients received a delayed cancer diagnosis, even when they had  
33  
34 presented with typical cancer symptoms to a GP who had access to relevant diagnostic tests  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
43.

## Possible implications for clinicians and policymakers

44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
PCP respondents from each participating country had specific recommendations on the  
changes that are needed to facilitate more timely diagnosis of cancer. Those responsible for  
the organisation of healthcare in their countries need to put this study's findings into the  
context of their own systems, so that they can identify which recommendations are  
particularly relevant in their own jurisdictions. Some recommendations, for instance health  
education campaigns and development of relevant guidelines, may need central direction,  
albeit with the input of PCPs. Others, for example improving the way PCP communicate with



secondary care specialists, and PCPs' ability to access to cancer-specific tests, may need local agreement. Aspects such as PCPs' own communication skills, their own accessibility to patients and their continuing medical education, are more likely to be under PCPs' own control. However, a consideration of how funding is best reallocated is crucial if PCPs and their health systems are able to make these changes.

### **Unanswered questions and future research**

Further analysis is needed to help identify which recommendations are most relevant to different existing models of healthcare, for example as to whether some are particularly relevant to systems in which the PCP has more of a 'gatekeeper' role, or to those in which PCP practises are large or smaller than average. A longitudinal study would give evidence on the trends on PCP opinions and how they are impacted by changes in health policies and public health initiatives. There is a need to consider how to get the best balance between achieving early cancer diagnosis and minimising overdiagnosis of cancer. Our study gives the basic elements for the international primary care cancer research agenda, which would provide a knowledgebase for developing and improving cancer diagnosis and prognosis internationally.

### **Conclusions**

This research has identified key features that PCPs believe would be necessary to improve the timeliness of cancer diagnosis in their patients, and a need for re-allocation of health system funding to allow these to happen. Health systems need to facilitate earlier patient presentation through health education and better access to care, have well-educated clinicians with good access to investigations and better information technology, and adequate primary care cancer diagnostic pathway funding.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Many PCPs play a crucial role at the centre of their patients' care, and the breadth of their experience is reflected in their wide range of suggestions. This understanding should help to inform health service policy and research towards better cancer outcomes.

For peer review only

## List of abbreviations

CME	Continuing medical education
GP	General practitioner
PCP	Primary Care Physician
UK	United Kingdom

## Declarations

### Ethics approval

Ethical approval for the study was given by the University of Bath Research Ethics Approval Committee for Health (approval date: 24th November 2014; REACH reference number: EP 14/15 66). Other countries' study leads either achieved local ethical approval or gave statements that formal ethical approval was not needed in their jurisdictions.

### Competing interests

The authors declare that they have no competing interests.

### Funding

This study received no specific grant from any funding agency in the public, commercial or not-for-profit sectors. ALN is supported by the National Institute for Health Research (NIHR) Imperial Patient Safety Translation Research Centre, with infrastructure support provided by the NIHR Imperial Biomedical Research Centre (BRC).

### Data sharing statement

The Örenäs survey data that support the findings of this study are available from the corresponding author, Harris M, upon reasonable request.

## Author contributions

1  
2 K Buczkowski, M Brekke, N Buono, E Costiug, G-J Dinant, M Esteva, G Foreva, M Harris, R  
3  
4 Hoffman, E Jakob, T Koskela, M Marzo-Castillejo, P Murchie, AL Neves, DP Petek, J Sawicka-  
5  
6 Powierza, A Schneider, E Smyrnakis, S Streit, H Thulesius, P Vedsted and B Weltermann  
7  
8 participated in the study design, piloting and data collection. G Taylor participated in the  
9  
10 study design. S Harker coded some of the data. M Esteva and S Harker assisted in validated the  
11  
12 coding. M Esteva, M Harris, R Hoffman, T Koskela, AL Neves, D Petek and H Thulesius worked  
13  
14 together to agree the themes. M Harris had overall responsibility for the study design,  
15  
16 recruitment of local leads, analysis of data and interpretation of results. All authors  
17  
18 contributed to the writing and review of the manuscript and approved the final version.  
19  
20  
21  
22  
23

## Acknowledgements

24  
25  
26  
27 The authors would like to thank all the PCPs who piloted the questionnaire and those who  
28  
29 completed the survey. They also thank the following non-author contributors: Isabelle Aubin-  
30  
31 Auger (Université Paris Diderot, Paris, France), Joseph Azuri (Tel Aviv University, Tel Aviv,  
32  
33 Israel), Svjetlana Gašparović Babić (The Teaching Institute of Public Health of Primorsko-  
34  
35 goranska County, Rijeka, Croatia) and Marija Petek Šter (University of Ljubljana, Ljubljana,  
36  
37 Slovenia).  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## References

1. Møller H, Linklater KM, Robinson D. A visual summary of the EURO CARE-4 results: a UK perspective. *Br J Cancer* 2009;101(Suppl 2):S110-4.
2. EURO CARE. EURO CARE-5. In: Istituto Nazionale Tumori (Milan IaISdSR, Italy), ed. Milan and Rome, 2014.
3. Maringe C, Walters S, Rachet B, et al. Stage at diagnosis and colorectal cancer survival in six high-income countries: a population-based study of patients diagnosed during 2000-2007. *Acta Oncol* 2013;52(5):919-32. doi: 10.3109/0284186X.2013.764008. Epub 2013 Apr 15.
4. Walters S, Maringe C, Coleman MP, et al. Lung cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK: a population-based study, 2004-2007. *Thorax* 2013;68(6):551-64. doi: 10.1136/thoraxjnl-2012-202297 [published Online First: 2013/02/13]
5. Richards M. The size of the prize for earlier diagnosis of cancer in England. *Br J Cancer* 2009;101 Suppl 2:S125-S29. doi: 10.1038/sj.bjc.6605402
6. Woods LM, Coleman MP, Lawrence G, et al. Evidence against the proposition that "UK cancer survival statistics are misleading": simulation study with National Cancer Registry data. *BMJ* 2011;342:d3399.(doi):10.1136/bmj.d3399.
7. Zahl PH, Jorgensen KJ, Gotzsche PC. Overestimated lead times in cancer screening has led to substantial underestimation of overdiagnosis. *Br J Cancer* 2013;109(7):2014-9. doi: 10.1038/bjc.2013.427. Epub 13 Aug 20.
8. Carter JL, Coletti RJ, Harris RP. Quantifying and monitoring overdiagnosis in cancer screening: a systematic review of methods. *BMJ* 2015;350:g7773.(doi):10.1136/bmj.g7773.
9. Peto J. Cancer epidemiology in the last century and the next decade. *Nature* 2001;411(6835):390-5. doi: 10.1038/35077256 [published Online First: 2001/05/18]
10. Popic T, Schneider SM. An East-West comparison of healthcare evaluations in Europe: Do institutions matter? *J Eur Soc Policy* 2018;28(5):517-34. doi: 10.1177/0958928717754294
11. Boscoe FP, Henry KA, Sherman RL, et al. The relationship between cancer incidence, stage and poverty in the United States. *Int J Cancer* 2016;139(3):607-12. doi: 10.1002/ijc.30087
12. Schrijvers C, Mackenbach J, Lutz J-M, et al. Deprivation and survival from breast cancer. *Br J Cancer* 1995;72(3):738. doi: 10.1038/bjc.1995.403
13. Mackie RM, Hole DJ. Incidence and thickness of primary tumours and survival of patients with cutaneous malignant melanoma in relation to socioeconomic status. *BMJ* 1996;312(7039):1125. doi: 10.1136/bmj.312.7039.1125
14. Butler J, Foot C, Bomb M, et al. The International Cancer Benchmarking Partnership: An international collaboration to inform cancer policy in Australia, Canada, Denmark, Norway, Sweden and the United Kingdom. *Health Policy* 2013;112(1):148-55.
15. Green T, Atkin K, Macleod U. Cancer detection in primary care: insights from general practitioners. *Br J Cancer* 2015;112:S41. doi: 10.1038/bjc.2015.41

16. Jacobsen MM, Silverstein SC, Quinn M, et al. Timeliness of access to lung cancer diagnosis and treatment: A scoping literature review. *Lung Cancer* 2017;112:156-64. doi: 10.1016/j.lungcan.2017.08.011 [published Online First: 2017/12/02]
17. McLaughlin JM, Anderson RT, Ferketich AK, et al. Effect on survival of longer intervals between confirmed diagnosis and treatment initiation among low-income women with breast cancer. *J Clin Oncol* 2012;30(36):4493-500. doi: 10.1200/jco.2012.39.7695 [published Online First: 2012/11/22]
18. Yun YH, Kim YA, Min YH, et al. The influence of hospital volume and surgical treatment delay on long-term survival after cancer surgery. *Ann Oncol* 2012;23(10):2731-7. doi: 10.1093/annonc/mds101 [published Online First: 2012/05/04]
19. Gobbi PG, Bergonzi M, Comelli M, et al. The prognostic role of time to diagnosis and presenting symptoms in patients with pancreatic cancer. *Cancer Epidemiol* 2013;37(2):186-90. doi: 10.1016/j.canep.2012.12.002 [published Online First: 2013/02/02]
20. Tørring ML, Frydenberg M, Hansen RP, et al. Evidence of increasing mortality with longer diagnostic intervals for five common cancers: a cohort study in primary care. *Eur J Cancer* 2013;49(9):2187-98. doi: 10.1016/j.ejca.2013.01.025 [published Online First: 2013/03/05]
21. Elit LM, O'Leary EM, Pond GR, et al. Impact of wait times on survival for women with uterine cancer. *J Clin Oncol* 2014;32(1):27-33. doi: 10.1200/jco.2013.51.3671 [published Online First: 2013/11/28]
22. Nanthamongkolkul K, Hanprasertpong J. Longer waiting times for early stage cervical cancer patients undergoing radical hysterectomy are associated with diminished long-term overall survival. *J Gynecol Oncol* 2015;26(4):262-9. doi: 10.3802/jgo.2015.26.4.262 [published Online First: 2015/09/26]
23. Neal R, Tharmanathan P, France B, et al. Is increased time to diagnosis and treatment in symptomatic cancer associated with poorer outcomes? Systematic review. *Br J Cancer* 2015;112 Suppl 1:S92-S107. doi: 10.1038/bjc.2015.48 [published Online First: 2015/03/04]
24. Olsson JK, Schultz EM, Gould MK. Timeliness of care in patients with lung cancer: a systematic review. *Thorax* 2009;64(9):749-56. doi: 10.1136/thx.2008.109330
25. Malmström M, Rasmussen BH, Bernhardson B-M, et al. It is important that the process goes quickly, isn't it?" A qualitative multi-country study of colorectal or lung cancer patients' narratives of the timeliness of diagnosis and quality of care. *Eur J Oncol Nurs* 2018;34:82-88. doi: 10.1016/j.ejon.2018.04.002
26. Foot C, Harrison T. How to improve cancer survival: explaining England's relatively poor rates. London: The King's Fund, 2011:30 January 2012.
27. Harris M, Frey P, Esteva M, et al. How health system factors influence referral decisions in patients that may have cancer: European symposium report. *J Cancer Res Ther* 2016;4(1):7-10. doi: 10.14312/2052-4994.2016-2
28. Johansen M-L, Holtedahl KA, Rudebeck CE. A doctor close at hand: How GPs view their role in cancer care. *Scand J Prim Health Care* 2010;28(4):249-55. doi: 10.3109/02813432.2010.526792
29. Adams E, Boulton M, Rose P, et al. Views of cancer care reviews in primary care: a qualitative study. *Br J Gen Pract* 2011;61(585):e173-e82. doi: 10.3399/bjgp11X567108

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
30. Mitchell GK, Burridge LH, Colquist SP, et al. General Practitioners' perceptions of their role in cancer care and factors which influence this role. *Health Soc Care Community* 2012;20(6):607-16. doi: 10.1111/j.1365-2524.2012.01075.x [published Online First: 2012/07/19]
  31. Perkins N, Coleman A, Wright M, et al. The 'added value' GPs bring to commissioning: a qualitative study in primary care. *Br J Gen Pract* 2014;64(628):e728-34. doi: 10.3399/bjgp14X682321
  32. Green T, Atkin K, Macleod U. GPs' perceptions and experiences of public awareness campaigns for cancer: a qualitative enquiry. *Health Expect* 2016;19(2):377-87. doi: 10.1111/hex.12362
  33. Harris M, Taylor G, Örenäs Research Group. How health system factors affect primary care practitioners' decisions to refer patients for further investigation: protocol for a pan-European ecological study. *BMC Health Serv Res* 2018;18(1):338. doi: 10.1186/s12913-018-3170-2
  34. Center for Aging in Diverse Communities. Guidelines for Translating Surveys in Cross-Cultural Research. San Francisco: University of California, 2007.
  35. Maneesriwongul W, Dixon JK. Instrument translation process: a methods review. *J Adv Nurs* 2004;48(2):175-86. doi: 10.1111/j.1365-2648.2004.03185.x [published Online First: 2004/09/17]
  36. Harris M, Vedsted P, Esteva M, et al. Identifying important health system factors that influence primary care practitioners' referrals for cancer suspicion: a European cross-sectional survey. *BMJ Open* 2018;8(9) doi: 10.1136/bmjopen-2018-022904
  37. Patton M. Qualitative Research & Evaluation Methods. Beverly Hills, CA: Sage 1990:177.
  38. Braun V, Clarke V. Using thematic analysis in psychology. *Qual Res Psychol* 2006;3(2):77-101. doi: 10.1191/1478088706qp063oa
  39. Daly H, Collins C. Barriers to early diagnosis of cancer in primary care: a needs assessment of GPs. *Ir Med J* 2007;100(10):624-6. [published Online First: 2008/02/19]
  40. Car LT, Papachristou N, Urch C, et al. Preventing delayed diagnosis of cancer: clinicians' views on main problems and solutions. *Journal of global health* 2016;6(2):020901. doi: 10.7189/jogh.06.020901 [published Online First: 2016/12/29]
  41. Rubin G, Vedsted P, Emery J. Improving cancer outcomes: better access to diagnostics in primary care could be critical. *Br J Gen Pract* 2011;61(586):317-18. doi: 10.3399/bjgp11X572283
  42. Rubin GP, Saunders CL, Abel GA, et al. Impact of investigations in general practice on timeliness of referral for patients subsequently diagnosed with cancer: analysis of national primary care audit data. *Br J Cancer* 2015;112(4):676-87. doi: 10.1038/bjc.2014.634
  43. Jiwa M, Meng X, O'Shea C, et al. How do general practitioners manage patients with cancer symptoms? A video-vignette study. *BMJ Open* 2015;5(9) doi: 10.1136/bmjopen-2015-008525

**Table 1.** National distribution of PCPs who responded to the question 'How do you think the speed of diagnosis of cancer in primary care could be improved?'

Country	Number of PCPs who completed the survey	Number who answered the open-ended question (% of all survey completers)
Bulgaria	52	45 (86.5)
Croatia	56	42 (75.0)
Denmark	92	71 (77.2)
England	62	25 (40.3)
Finland	61	39 (63.9)
France	52	35 (67.3)
Germany	91	31 (34.1)
Greece	59	50 (84.7)
Israel	58	42 (72.4)
Italy	60	52 (86.7)
Netherlands	108	84 (77.8)
Norway	81	46 (56.8)
Poland	135	103 (76.3)
Portugal	59	46 (78.0)
Romania	146	132 (90.4)
Scotland	62	55 (88.7)



Slovenia	91	52 (57.1)
Spain	380	332 (87.4)
Sweden	68	55 (80.9)
Switzerland	60	15 (25.0)
Total	1,833	1,352 (73.8)

For peer review only

**Table 2.** Demographic distribution of PCPs who responded to the question ‘How do you think the speed of diagnosis of cancer in primary care could be improved?’

Demographic	Number (%)
Gender	
Female	833 (61.6)
Male	513 (38.0)
Not stated	5 (0.4)
Years since graduation	
<10	192 (14.2)
10–19	356 (26.4)
20–29	416 (30.8)
30–39	336 (24.9)
40 or over	47 (3.5)
Not stated	4 (0.3)
Site of practice	
Urban	816 (60.4)
Rural	314 (23.2)
Island	25 (1.9)

Mixed	194 (14.4)
Not stated	2 (0.1)
Number of doctors in practice	
1-2	337 (24.9)
3-5	344 (25.5)
6-9	290 (21.5)
10 or more	374 (27.7)
Not stated	6 (0.4)

For peer review only

## Figure legends

1  
2  
3 **Figure 1.** *Diagrammatic representation of themes emerging from responses to the question:*  
4  
5 *'How do you think the speed of diagnosis of cancer in primary care could be improved?'*  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only




Figure 1. Diagrammatic representation of themes emerging from responses to the question: 'How do you think the speed of diagnosis of cancer in primary care could be improved?'

292x200mm (300 x 300 DPI)

## Supplementary file. Ethical and other approvals obtained in each Örenäs Research Group participating jurisdiction

	Date of Ethics Approval	Approvals obtained	Reference
Bulgaria	29 October 2015	Medical University Plovdiv Ethical Commission	P-7820
Croatia	16 December 2016	Nastavni Zovod Za Javno Zdravstvo	08-820-61/31-15
Denmark	7 May 2016	Danish Data Protection Agency; according to Danish law and the Central Denmark Region Committees on Health Research Ethics, approval by the National Committee on Health Research Ethics was not required as no biomedical intervention was performed.	2009-41-3471
Finland	16 November 2016	Academic Ethics Committee of the Tampere Region	16 November 2016
France	N/A	In France, research ethics approval was not required as no biomedical intervention was performed.	
Germany	15 January 2016	Ethik-Kommission Universität Duisberg-Essen	16-6747-BO
Greece	N/A	In Greece, research ethics approval was not required as no biomedical intervention was performed.	
Israel	N/A	In Israel, research ethics approval was not required as no biomedical intervention was performed.	
Italy	N/A	In Italy the approval of the ethical committee is not required when a study is neither an interventional nor an observational study on pharmacological treatment.	Decreto Legislativo n. 211 (24 giugno 2003)<2001/20/EC
Netherlands	27 June 2016	medisch-ethischetoetsingscommissie (METC) azM/UM Maastricht UMC+	METC 16-4-113
Norway	N/A	In Norway, research ethics approval was not required as no biomedical intervention was performed.	
Poland	28 January 2016	Komisja Bioetyczna Uniwersytetu Medycznego w Białymstoku	R_I_022/10/2016

1 2 3	Portugal	N/A	In Portugal, research ethics approval was not required as no biomedical intervention was performed.	
4 5 6 7	Romania	N/A	In Romania, research ethics approval was not required as no biomedical intervention was performed.	
8 9	Slovenia	8 December 2014	Komisija Republike Slovenije Medicinsko Etiko	KME 113/08/14
10 11 12 13 14 15 16	Spain	25 October 2015 23 Decmber 2015	Comissio d'Investigacio Govern de les Illes Balears Informe del Comite Etic d'Investigacio Clinica	Palma 27oct15 P15/159
17 18 19 20 21 22 23 24	Sweden	N/A	In Sweden, research ethics approval was not required as no biomedical intervention was performed. It does not fall under the law of research on human subjects to ask professionals about their work and how they perceive it.	
25 26 27 28 29 30 31	Switzerland	N/A	Swiss law on human research (Humanforschungsgesetz, HFG) does not require that an ethics committee approve collection and analysis of non-medical and anonymous data.	
32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60	United Kingdom	24 November 2014	Research Ethics Approval Committee for Health, University of Bath	EP 14/15 66

# Reporting checklist for qualitative study.

Based on the SRQR guidelines.

## Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the SRQR reporting guidelines, and cite them as:

O'Brien BC, Harris IB, Beckman TJ, Reed DA, Cook DA. Standards for reporting qualitative research: a synthesis of recommendations. *Acad Med.* 2014;89(9):1245-1251.

	Reporting Item	Page Number
	<a href="#">#1</a> Concise description of the nature and topic of the study identifying the study as qualitative or indicating the approach (e.g. ethnography, grounded theory) or data collection methods (e.g. interview, focus group) is recommended	1
	<a href="#">#2</a> Summary of the key elements of the study using the abstract format of the intended publication; typically includes background, purpose, methods, results and conclusions	4-5
Problem formulation	<a href="#">#3</a> Description and significance of the problem / phenomenon studied: review of relevant theory and empirical work; problem statement	7-8
Purpose or research question	<a href="#">#4</a> Purpose of the study and specific objectives or questions	8
Qualitative approach and research paradigm	<a href="#">#5</a> Qualitative approach (e.g. ethnography, grounded theory, case study, phenomenology, narrative research) and guiding theory if appropriate; identifying the research paradigm (e.g. postpositivist, constructivist / interpretivist) is also	9-10



recommended; rationale. The rationale should briefly discuss the justification for choosing that theory, approach, method or technique rather than other options available; the assumptions and limitations implicit in those choices and how those choices influence study conclusions and transferability. As appropriate the rationale for several items might be discussed together.

1			
2			
3			
4			
5			
6			
7			
8			
9			
10	Researcher characteristics	<a href="#">#6</a>	10-11
11	and reflexivity	Researchers' characteristics that may influence the research, including personal attributes, qualifications / experience, relationship with participants, assumptions and / or presuppositions; potential or actual interaction between researchers' characteristics and the research questions, approach, methods, results and / or transferability	
12			
13			
14			
15			
16			
17			
18			
19			
20	Context	<a href="#">#7</a>	9-10
21		Setting / site and salient contextual factors; rationale	
22	Sampling strategy	<a href="#">#8</a>	10
23		How and why research participants, documents, or events were selected; criteria for deciding when no further sampling was necessary (e.g. sampling saturation); rationale	
24			
25			
26			
27	Ethical issues pertaining	<a href="#">#9</a>	10; 24
28	to human subjects	Documentation of approval by an appropriate ethics review board and participant consent, or explanation for lack thereof; other confidentiality and data security issues	
29			
30			
31			
32			
33	Data collection methods	<a href="#">#10</a>	9-10
34		Types of data collected; details of data collection procedures including (as appropriate) start and stop dates of data collection and analysis, iterative process, triangulation of sources / methods, and modification of procedures in response to evolving study findings; rationale	
35			
36			
37			
38			
39			
40			
41	Data collection	<a href="#">#11</a>	9
42	instruments and	Description of instruments (e.g. interview guides, questionnaires) and devices (e.g. audio recorders) used for data collection; if / how the instruments(s) changed over the course of the study	
43	technologies		
44			
45			
46			
47			
48	Units of study	<a href="#">#12</a>	11
49		Number and relevant characteristics of participants, documents, or events included in the study; level of participation (could be reported in results)	
50			
51			
52			
53	Data processing	<a href="#">#13</a>	10
54		Methods for processing data prior to and during analysis, including transcription, data entry, data management and security, verification of data integrity, data coding, and anonymisation / deidentification of excerpts	
55			
56			
57			
58			
59			
60			

1	Data analysis	<a href="#">#14</a>	Process by which inferences, themes, etc. were identified and developed, including the researchers involved in data analysis; usually references a specific paradigm or approach; rationale	10
2				
3				
4				
5				
6	Techniques to enhance trustworthiness	<a href="#">#15</a>	Techniques to enhance trustworthiness and credibility of data analysis (e.g. member checking, audit trail, triangulation); rationale	10
7				
8				
9				
10				
11	Syntheses and interpretation	<a href="#">#16</a>	Main findings (e.g. interpretations, inferences, and themes); might include development of a theory or model, or integration with prior research or theory	11-19
12				
13				
14				
15				
16				
17	Links to empirical data	<a href="#">#17</a>	Evidence (e.g. quotes, field notes, text excerpts, photographs) to substantiate analytic findings	11-19
18				
19				
20				
21	Intergration with prior work, implications, transferability and contribution(s) to the field	<a href="#">#18</a>	Short summary of main findings; explanation of how findings and conclusions connect to, support, elaborate on, or challenge conclusions of earlier scholarship; discussion of scope of application / generalizability; identification of unique contributions(s) to scholarship in a discipline or field	19-21
22				
23				
24				
25				
26				
27				
28				
29	Limitations	<a href="#">#19</a>	Trustworthiness and limitations of findings	20
30				
31	Conflicts of interest	<a href="#">#20</a>	Potential sources of influence of perceived influence on study conduct and conclusions; how these were managed	24
32				
33				
34				
35	Funding	<a href="#">#21</a>	Sources of funding and other support; role of funders in data collection, interpretation and reporting	24
36				
37				
38				

39 The SRQR checklist is distributed with permission of Wolters Kluwer © 2014 by the Association of American  
 40 Medical Colleges. This checklist can be completed online using <https://www.goodreports.org/>, a tool made by  
 41 the [EQUATOR Network](#) in collaboration with [Penelope.ai](#)  
 42  
 43  
 44  
 45  
 46  
 47  
 48  
 49  
 50  
 51  
 52  
 53  
 54  
 55  
 56  
 57  
 58  
 59  
 60

# BMJ Open

## How European primary care practitioners think the timeliness of cancer diagnosis can be improved – a thematic analysis

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-030169.R1
Article Type:	Original research
Date Submitted by the Author:	18-Jun-2019
Complete List of Authors:	<p>Harris, Michael; University of Bath, Department for Health; University of Bern, Berner Institut für Hausarztmedizin (BIHAM)</p> <p>Thulesius, Hans; Lund University, Department of Clinical Sciences; Department of Research and Development</p> <p>Neves, Ana Luísa; Imperial College London, Institute of Global Health Innovation; University of Porto, CINTESIS (Centre for Health Technology and Services Research) and MEDCIDS (Department of Community Medicine, Information and Health Decision Sciences), Faculty of Medicine</p> <p>Harker, Sophie; University of Bath, Department for Health</p> <p>Koskela, Tuomas; Tampere University, Faculty of Medicine and Health Technology</p> <p>Petek, Davorina; Univerza v Ljubljani, Department of Family Medicine</p> <p>Hoffman, Robert; Tel Aviv University, Department of Family Medicine</p> <p>Brekke, Mette; University of Oslo, Department of General Practice and General Practice Research Unit</p> <p>Buczowski, Krzysztof; Nicolaus Copernicus University, Department of Family Medicine</p> <p>Buono, Nicola; SNAMID, Family medicine</p> <p>Costiug, Emiliana; Universitatea de Medicina si Farmacie Iuliu Hatieganu, Family Medicine Department</p> <p>Dinant, Geert-Jan; Maastricht University, Dept of General Practice</p> <p>Foreva, Gergana; Medical Center BROD</p> <p>Jakob, Eva; Centro de Saúde Sarria, Primary Health Centre</p> <p>Marzo, Mercè; Unitat de Suport a la Recerca Costa de Ponent, IDIAP</p> <p>Jordi Gol,</p> <p>Murchie, Peter; University of Aberdeen, Division of Applied Health Science</p> <p>Sawicka-Powierza, Jolanta; Uniwersytet Medyczny w Białymstoku, Department of Family Medicine</p> <p>Schneider, Antonius; Technical University of Munich, TUM School of Medicine, Institute of General Practice and Health Services Research</p> <p>Smyrnakis, Emmanouil; Aristotle University of Thessaloniki, Laboratory of Primary Health Care, General Practice and Health Services Research</p> <p>Streit, Sven; University of Bern, Berner Institut für Hausarztmedizin (BIHAM)</p> <p>Taylor, Gordon; University of Exeter, College of Medicine and Health</p> <p>Vedsted, Peter; Research Unit for General Practice, University of Aarhus</p> <p>Weltermann, Birgitta; University of Bonn, Institut für Hausarztmedizin</p> <p>Esteva, Magdalena; Gerencia Atencio Primaria de Mallorca, Unidad de</p>

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

	Investigación
<b>Primary Subject Heading</b> :	General practice / Family practice
<b>Secondary Subject Heading</b> :	Oncology, Qualitative research, Public health
<b>Keywords</b> :	Delivery of Health Care, Primary Health Care, General Practitioners, Cancer, Diagnosis, Consultation and Referral



# How European primary care practitioners think the timeliness of cancer diagnosis can be improved – a thematic analysis

Michael Harris <sup>1,2</sup> (corresponding author), michaelharris681@btinternet.com

Hans Thulesius <sup>3,4</sup>, hansthulesius@gmail.com

Ana Luísa Neves <sup>5,6</sup>, ana.luisa.neves@gmail.com

Sophie Harker <sup>1</sup>, sophie.888@btinternet.com

Tuomas Koskela <sup>7</sup>, tuomas.koskela@tuni.fi

Davorina Petek <sup>8</sup>, davorina.petek@gmail.com

Robert D. Hoffman <sup>9</sup>, hofman\_r@mac.org.il

Mette Brekke <sup>10</sup>, mette.brekke@medisin.uio.no

Krzysztof Buczkowski <sup>11</sup>, buczkowskik@cm.umk.pl

Nicola Buono <sup>12</sup>, buono.nicola2@gmail.com

Emiliana Costiug <sup>13</sup>, dr.costiug@gmail.com

Geert-Jan Dinant <sup>14</sup>, geertjan.dinant@maastrichtuniversity.nl

Gergana Foreva <sup>15</sup>, gerganaforeva@gmail.com

Eva Jacob <sup>16</sup>, eva.jacob.gonzalez@sergas.es

Mercè Marzo-Castillejo <sup>17</sup>, mmarzoc@gencat.cat

Peter Murchie <sup>18</sup>, p.murchie@abdn.ac.uk

Jolanta Sawicka-Powierza <sup>19</sup>, jolasawicka@gmail.com

Antonius Schneider <sup>20</sup>, antonius.schneider@tum.de

Emmanouil Smyrnakis <sup>21</sup>, smyrnak@auth.gr

Sven Streit <sup>2</sup>, sven.streit@biham.unibe.ch

Gordon Taylor <sup>22</sup>, g.j.taylor@exeter.ac.uk

Peter Vedsted <sup>23</sup>, p.vedsted@alm.au.dk

Birgitta Weltermann <sup>24</sup>, birgitta.weltermann@ukbonn.de

Magdalena Esteva <sup>25</sup>, mesteva@ibsalut.caib.es

<sup>1</sup> Department for Health, University of Bath, Claverton Down, Bath BA2 7AY, UK; telephone: +44 1761 241366; fax: none.

<sup>2</sup> Institute of Primary Health Care Bern (BIHAM), University of Bern, Bern, Switzerland

<sup>3</sup> Department of Clinical Sciences, Lund University, Malmö, Sweden

<sup>4</sup> Department of Research and Development, Region Kronoberg, Sweden

<sup>5</sup> Institute of Global Health Innovation, Imperial College, London, UK.

<sup>6</sup> CINTESIS (Centre for Health Technology and Services Research) and MEDCIDS (Department of Community Medicine, Information and Health Decision Sciences), Faculty of Medicine, University of Porto, Porto, Portugal

<sup>7</sup> Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.

<sup>8</sup> Department of Family Medicine, University of Ljubljana, Ljubljana, Slovenia.

<sup>9</sup> Department of Family Medicine, Tel Aviv University, Tel Aviv, Israel.

<sup>10</sup> Department of General Practice and General Practice Research Unit, University of Oslo, Oslo, Norway.

<sup>11</sup> Department of Family Medicine, Nicolaus Copernicus University, Toruń, Poland.

<sup>12</sup> Department of General Practice, National Society of Medical Education in General Practice (SNaMID), Caserta, Italy.

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50
- <sup>13</sup> Family Medicine Department, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania.
- <sup>14</sup> Department of General Practice, Maastricht University, Maastricht, Netherlands.
- <sup>15</sup> Medical Center BROD, Plovdiv, Bulgaria
- <sup>16</sup> Primary Health Centre, Centro de Saúde Sarria, Sarria, Lugo, Spain.
- <sup>17</sup> Unitat de Suport a la Recerca, IDIAP Jordi Gol, Institut Català de la Salut, Barcelona, Spain.
- <sup>18</sup> Division of Applied Health Sciences - Academic Primary Care, University of Aberdeen, Aberdeen, UK.
- <sup>19</sup> Department of Family Medicine, Medical University of Bialystok, Bialystok, Poland.
- <sup>20</sup> TUM School of Medicine, Institute of General Practice and Health Services Research, Technical University of Munich, Munich, Germany.
- <sup>21</sup> Laboratory of Primary Health Care, General Practice and Health Services Research, Aristotle University of Thessaloniki, Thessaloniki, Greece.
- <sup>22</sup> College of Medicine and Health, University of Exeter, Exeter, UK.
- <sup>23</sup> The Research Unit for General Practice, Aarhus University, Aarhus, Denmark.
- <sup>24</sup> Institut für Hausarztmedizin, University of Bonn, Bonn, Germany.
- <sup>25</sup> Research Unit, Majorca Primary Health Care Department, Balearic Islands Health Research Institute (IdISBa), Preventive Activities and Health Promotion Network, Carlos III Institute of Health (RedIAPP-RETICS), Palma, Spain.

51  
52  
53

### Keywords

54 Delivery of Health Care; Primary Health Care; General Practitioners; Cancer; Diagnosis;  
55  
56 Consultation and Referral.  
57  
58  
59  
60

**Word count**

3,182 (excluding data/quotes)

**Abstract****Background**

National European cancer survival rates vary widely. Prolonged diagnostic intervals are thought to be a key factor in explaining these variations. Primary Care Practitioners (PCPs) frequently play a crucial role during initial cancer diagnosis; their knowledge could be used to improve the planning of more effective approaches to earlier cancer diagnosis.

**Objectives**

This study sought the views of PCPs from across Europe on how they thought the timeliness of cancer diagnosis could be improved.

**Design**

In an online survey, a final open-ended question asked PCPs how they thought the speed of diagnosis of cancer in primary care could be improved. Thematic analysis was used to analyse the data.

**Setting**

A primary care study, with participating centres in twenty European countries.

**Participants**

A total of 1,352 PCPs answered the final survey question, with a median of 48 per country.

**Results**

The main themes identified were: patient-related factors, including health education; care provider-related factors, including continuing medical education; improving communication



1  
2  
3  
4  
5  
6  
7  
8  
9  
and inter-professional partnership, particularly between primary and secondary care; factors  
relating to health system organization and policies, including improving access to health care;  
easier primary care access to diagnostic tests; and use of information technology. Re-  
allocation of funding to support timely diagnosis was seen as an issue affecting all of these.

## 10 **Conclusions**

11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
To achieve more timely cancer diagnosis, health systems need to facilitate earlier patient  
presentation through education and better access to care, have well-educated clinicians with  
good access to investigations and better information technology, and adequate primary care  
cancer diagnostic pathway funding.

## Article Summary

### Strengths and limitations of this study

- We recruited PCPs from 20 European countries, four countries from each of the Northern, Southern, Eastern, Western and Central European geographical areas, to provide variation in geography, health systems and levels of healthcare spending.
- The recruitment method allowed participation of physicians in countries in which PCPs are underrepresented in research.
- The survey had only one question that related directly to PCPs' views on the timeliness of cancer diagnosis.
- Neither patients, secondary care nor other primary care health professionals were included in the survey, and these groups may have had other insights to offer.

## Introduction

1  
2  
3 Cancer survival rates vary widely in Europe <sup>1</sup>, leading to considerable additional mortality in  
4  
5 some countries. Data from the European Cancer Registry-based Study on Survival and Care of  
6  
7 Cancer Patients (EUROCARE-5) show that the national 1-year relative survival rates for all  
8  
9 cancer sites vary from 58.2% to 81.1% <sup>2</sup>. Poorer 1-year relative survival is thought to be  
10  
11 indicative of diagnostic delay <sup>3 4</sup> and more advanced disease at diagnosis <sup>5 6</sup>, although it can be  
12  
13 affected by differences in registration, as well as overdiagnosis and lead-time biases <sup>7 8</sup>. There  
14  
15 may also be geographical differences in incidence of cancers that have a poorer prognosis <sup>9</sup>, as  
16  
17 well as national variations in access to effective cancer treatment <sup>10</sup>, and in levels of poverty,  
18  
19 which in itself has been linked with more advanced disease stage at diagnosis <sup>11-13</sup>. More  
20  
21 advanced cancers are more difficult to treat successfully <sup>14</sup> and, for many cancers, the stage of  
22  
23 disease at diagnosis is related to survival <sup>15 16</sup>. There is considerable evidence that longer time  
24  
25 to diagnosis and treatment has an adverse impact on cancer mortality <sup>17-23</sup>. Timely care also  
26  
27 adds to patients' quality of life and emotional well-being <sup>24</sup>. In addition, patients' descriptions  
28  
29 of the quality of their care are closely related to the speed of their diagnosis and treatment;  
30  
31 this is because they are concerned that longer waits might allow time for their cancers to  
32  
33 grow <sup>25</sup>.

34  
35  
36  
37  
38  
39  
40  
41 Timely diagnosis of cancer has therefore been an important aim of healthcare providers  
42  
43 across Europe <sup>25</sup>. However, the challenge in deciding where and how to achieve this is  
44  
45 substantial <sup>26</sup>. In countries where a comparatively low 1-year cancer survival suggests that  
46  
47 late diagnosis may be a major factor, it is uncertain whether this is due to patients presenting  
48  
49 later to health-care, whether they are not being referred quickly enough by those in primary  
50  
51 care, or whether they are not being investigated and managed efficiently in secondary care <sup>14</sup>.  
52  
53 This may be a particular problem where patients with cancer present without red-flag  
54  
55 symptoms, as how their primary care practitioners (PCPs) act depends on how their health  
56  
57 systems are organised <sup>27</sup>.  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Doctors and their patients recognise that general practitioners (GPs) and other PCPs have a key role in cancer detection <sup>28-30</sup>. It has been suggested that PCPs' knowledge of their patient populations can be used to improve health service design <sup>31</sup> and the planning for more effective approaches to earlier cancer recognition and referral <sup>32</sup>. There has been a call for research in this field <sup>15</sup>; although PCPs' experience of their own health systems could potentially help to improve the planning of more effective approaches to earlier cancer recognition and referral, their perceptions have not been previously evaluated.

The aim of this study was to elicit the views of GPs and other PCPs from across Europe on how they thought the timeliness of cancer diagnosis could be improved.

## Methods and design

### Design

Between November 2015 and December 2016, we performed an online survey of PCPs in 20 European countries. The methodology of the study is described in our published protocol paper <sup>33</sup>.

### Development of the questionnaire

The Örenäs Research Group is a European group of primary care researchers that studies the primary care factors that relate to cancer survival. After a literature review, Örenäs Research Group investigators developed a questionnaire designed to elicit PCPs' referral decisions on patients that could have cancer, and their degree of agreement with items relating to health system aspects that could affect their decision to refer patients with potential cancer symptoms for further investigation. The final, open-ended question asked: 'How do you think the speed of diagnosis of cancer in primary care could be improved?' The answers to this question are used in this analysis.

The questionnaire was piloted twice by PCPs in 16 Örenäs Research Group centres. No changes were made to the final, open-ended question after either of the piloting stages. Örenäs Research Group leads arranged for translations of the questionnaire into their local languages where these were not English, a total of 19 translations from the original English. Translation, validation by back-translation to assess semantic and conceptual equivalence, and cultural adaptation <sup>34</sup> of the survey were done in a standardised way <sup>35</sup> and are described elsewhere <sup>36</sup>. The questionnaires were put online using SurveyMonkey (SurveyMonkey, California, USA).

## Participants and recruitment

1  
2 The study was conducted in 25 Örenäs Research Group centres in 20 countries across Europe:  
3  
4 Bulgaria, Croatia, Denmark, England, Finland, France, Germany, Greece, Israel, Italy,  
5  
6 Netherlands, Norway, Poland, Portugal, Romania, Scotland, Slovenia, Spain, Sweden and  
7  
8 Switzerland. Local study leads were asked to either gain ethical approval or obtain a  
9  
10 statement that formal ethical approval was not needed in their jurisdiction (see  
11  
12 supplementary file).  
13  
14  
15

16  
17 Criterion sampling was used<sup>37</sup>, with subjects being eligible for the survey if they were doctors  
18  
19 working mainly in primary care. These doctors, referred to collectively here as 'Primary Care  
20  
21 Practitioners', consisted of GPs as well as other doctors who had specialist training but  
22  
23 worked in the community and could be accessed directly by patients without referral.  
24  
25

26  
27 Each Örenäs Research Group local lead was asked to email a survey invitation to the PCPs in  
28  
29 their local health district, and to recruit at least 50 participants, with no maximum limit. This  
30  
31 allowed recruitment of a varied sample with regards to gender, years since graduation, site of  
32  
33 practice (urban, rural, remote), and size of practice. Consent was implied by agreeing to take  
34  
35 part in the survey.  
36  
37  
38

## Data analysis

39  
40  
41  
42 Local Örenäs Research Group leads translated the responses from their own languages into  
43  
44 English and sent them to MH, who asked them for more information where the translation or  
45  
46 context was unclear.  
47  
48

49  
50 We used inductive thematic analysis<sup>38</sup>, an approach in which codes and themes are suggested  
51  
52 by the data rather than by a theoretical framework. The phases of analysis included coding,  
53  
54 followed by the identification and clustering of themes and sub-themes, and the production of  
55  
56 a descriptive thematic summary. Two researchers (MH and SH) independently coded the data  
57  
58 from three countries and compared their analyses for inconsistencies and agreement. MH  
59  
60

1 then coded the data from the other countries. Team members from seven participating  
2 countries (ME, MH, RH, TK, ALN, DP, HT, all PCPs) then independently considered themes and  
3 sub-themes, discussed these and came to a consensus over the course of two meetings. The  
4 themes and sub-themes were grouped to construct an interpretative narrative across the  
5 dataset and depicted diagrammatically. Apart from SH, a Masters psychology student, all  
6 authors involved in the coding and thematic analysis were experienced general practitioners  
7 who were also active in primary care research.  
8  
9  
10  
11  
12  
13  
14  
15

### 16 **Patient and public involvement**

17  
18  
19 There was no patient or public involvement in this study.  
20  
21  
22

### 23 **Results**

24  
25  
26 A total of 1,833 PCPs completed the full questionnaire, with a median response rate per  
27 country of 24.8% (range 7.1% to 65.6%). All participating centres received at least 50  
28 responses, with a median of 61 PCPs per country. In all, 1,352 PCPs (73.8% of completers)  
29 gave an answer to the final, open-ended survey question 'How could the speed of diagnosis of  
30 cancer in primary care could be improved?', with a median of 48 per country (Table 1). To  
31 reduce the risk of bias from countries with larger numbers of respondents, we coded a  
32 maximum of 100 respondents' comments, randomly sampled, per country. The demographic  
33 distributions of the PCPs answering this final survey question are shown in Table 2. Towards  
34 the end of the analysis, no new themes emerged.  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47

48 We identified four main themes organising the content of the responses to the final survey  
49 question: patient-related factors, care provider-related features, improving communication  
50 and inter-professional partnership, and aspects of health system organisation and health  
51 policies. Two structural facets transcended the four themes: accessing diagnostic tests and  
52 using information technology. The issue of allocating funding to support timely diagnosis fed  
53 into all the other themes. The themes are shown diagrammatically in Figure 1. Themes and  
54  
55  
56  
57  
58  
59  
60

subthemes are described below, with participant quotations identified by country and a participant number.

**(Place Figure 1 here)**

### **Patient-related factors**

This theme included ideas on education and training to improve patient knowledge. Many PCPs advocated the use of health education and media campaigns to improve patient awareness of alarm symptoms and signs:

‘By giving patients better information about when to go to a doctor - reduce patient delay.’ (Denmark, PCP69)

‘Improve health literacy of patients regarding the detection of early symptoms that might indicate oncological disease.’ (Portugal, PCP37)

Targeting advice on cancer risks was also considered important:

‘Informing patients about cancer risks related to their age groups.’ (Italy, PCP28)

However, public health messages could be seen as unworkable:

‘Stop public campaigns telling everyone with a particular symptom they need e.g. a chest X-ray after 3 weeks of cough – inappropriately blocking the service.’ (Scotland, PCP16)

### **Care provider-related factors**

PCPs had suggestions on how to improve their own knowledge and that of other caregivers, by both increasing the amount of the training and improving the teaching content. Improving the training of PCPs and other health care professionals was considered by many respondents to be important:



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

'By educating health care professionals. When to suspect and when to do further tests?'

(Finland, PCP33)

'CME [continuing medical education] on early signs and up-to-date investigation processes.' (Sweden, PCP52)

Alertness in their role was also considered key:

'Often the presence of alarm signs is too late ... Be alert and listen to the patients.'  
(Spain, PCP46)

Primary care doctors also need to be aware of the relevant clinical pathways:

'Training of GPs ... taking into account the entire pathway from symptom to diagnosis.'  
(Poland, PCP17)

PCPs thought it important that cancer screening and referral guidelines should be clear, and that they themselves should be involved in designing them.

'Clear guidelines regarding cancer alarm signs and referral indications.' (Finland, PCP37)

'GPs who design guidelines together with specialists.' (Sweden, PCP21)

### **Improving communication and inter-professional partnership**

Patient-PCP communication improvements and enhancements to inter-professional partnerships were frequently suggested by the PCP respondents. Improving communication with patients was considered important, though this implied having longer consultations:

'GPs should pay more attention when they speak to patients.' (Italy, PCP26)

'Longer consultations to allow more thorough assessment without pressure of time.'  
(Scotland, PCP5)

Improving the interaction within the practice team could also be helpful:

1 'Discussion in the team about recent referrals so the team benchmarks itself.' (England,  
2 PCP22)

3  
4 'A lot can be learnt from colleagues' experiences of missed diagnoses.' (Netherlands,  
5  
6  
7 PCP40)

8  
9  
10 Improving partnership between PCPs and other primary health care professionals, for  
11  
12 example nurses and health-care assistants, with adequate training, was also considered  
13  
14 important:

15  
16  
17 'Involve the nurses in gathering the patient's medical history.' (Poland, PCP20)

18  
19  
20 'Good training of health-care assistant to identify risk symptoms.' (Norway, PCP1)

21  
22  
23 Improving the relationship between primary and secondary care doctors, with easier and  
24  
25 reliable communication between the two, was highlighted:

26  
27  
28 'Easy communication with specialists (and, in my case, preferably email contact).'

29  
30  
31 (Netherlands, PCP85)

32  
33  
34 'It is essential to establish a communication channel between primary health care and  
35  
36 specialist health care so that critical patients would not get lost in the system.' (Croatia,  
37  
38 PCP36)

39  
40  
41 Joint working with public health departments was also considered valuable:

42  
43  
44 'With the cooperation between the National Institute of Public Health and family  
45  
46 medicine specialists, who know their patients best.' (Croatia, PCP38)

47  
48  
49 Many doctors commented on the importance of continuity of care:

50  
51  
52 'Knowing your patient well. Consequently, not having three different GPs for one  
53  
54 patient.' (Netherlands, PCP69)

## Strengthening system organisation and improving health policy

Strengthening how health systems are organised and implementing health policies that allow timely cancer diagnosis were key recommendations from many PCPs. Enhancing patient access to primary care, particularly for vulnerable or more remote groups, was considered important by some:

‘Shorter queues to GP appointment in order to start assessments without delay.’

(Finland, PCP33)

‘In some places (rural, inland) inaccessibility to MCDTs [screening examinations] can be an obstacle.’ Portugal, PCP43)

Practical steps to improve access to secondary care were also seen as key, particularly those relating to costs to the patient:

‘Access to specialists must be cheaper.’ (Romania, PCP99)

‘Patient friendly hospital services - so that the appointments are not too stressful or expensive (travel and parking).’ (England, PCP19)

Many PCPs commented on the need for better working conditions, a larger workforce, a reduced workload and less bureaucracy:

‘A sufficient number of healthcare professionals so that there is not too much workload for a few.’ (Croatia, PCP5)

‘Reduction of the workload at the family medicine doctor office.’ (Croatia, PCP31)

‘By decreasing bureaucracy! So we will have more time for a real consultation!’

(Romania, PCP49)

The adoption of financial incentives schemes was also suggested:

‘Allocating additional financial resources and stimulating the GP in this direction.’

(Romania, PCP78)

1 'Financial incentives for preventative care of most common malignant conditions.'

2 (Bulgaria, PCP4)

3  
4  
5 PCPs felt that guidelines and protocols needed to be clear and relevant to them:

6  
7 'Clear guidelines regarding cancer alarm signs and referral indications.' (Finland,

8  
9  
10 PCP37)

11  
12 'By developing a more specific GP protocol for the various types of cancer.'

13  
14  
15 (Netherlands, PCP51)

16  
17  
18 Fast-track systems for patients with cancer were requested by many respondents:

19  
20 'Create a fast-track unit for patients with high cancer suspicion.' (Spain, PCP51)

21  
22 'Preferential appointments for cases with cancer suspicion in all hospital specialities.'

23  
24  
25 (Spain, PCP6)

26  
27  
28 In countries where fast-track systems already existed, these were seen as a success:

29  
30  
31 'Cancer diagnostics have priority in the Norwegian health care system since fast track  
32 referral was introduced last year. Functions well.' (Norway, PCP5)

33  
34  
35 'I actually think that the introduction of the "2-week wait" urgent referral system has  
36 greatly improved the speed of diagnosis for those with obvious red flag symptoms.'

37  
38  
39 (England, PCP11)

40  
41  
42 Some PCPs felt that there should be more uptake of national screening programmes:

43  
44  
45 'Encourage patients to use existing prevention programmes.' (Germany, PCP7)

46  
47  
48 'All physicians should adhere to screening guidelines.' (Switzerland, PCP8)

49  
50  
51

52  
53  
54

55  
56  
57

58  
59  
60

## Accessing diagnostic tests

This theme suggesting improvements to diagnostic structures dealt mainly with easier and quicker access to testing. Easier PCP access to diagnostic testing was cited by many respondents:

‘Increasing the range of diagnostics available; also making them easier to refer for.’  
(Netherlands, PCP79)

‘Facilitating family doctors to request tests and investigations that he/she considers necessary for the diagnosis.’ (Spain, PCP39)

Many felt that they should have direct access to cancer-specific testing:

‘GPs should be able to recommend any investigation without reference to other specialist doctors.’ (Romania, PCP44)

‘Give GPs the ability to refer patients to more diagnostic tests e.g. CT, tumour markers.’  
(Poland, PCP26)

The speed of access to diagnostic tests was also seen as key:

‘Faster access/fast track to imaging diagnostics could help us exclude a number of cases and so could relieve specialist services.’ (Norway, PCP18)

‘Reduction of the delay in getting special tests.’ (France, PCP 2)

However, some PCPs were worried that the increase in investigation of patients needed to diagnose cancers earlier could also lead to overdiagnosis and overtreatment:

‘Cancer diagnostics are a difficult balancing act between under- and overdiagnosis. Faster cancer diagnostics will also give more overdiagnosis.’ (Norway, PCP 31)

‘Depends on the type of cancer, but there is a trade-off between diagnosing a few cancers earlier by referring lots more patients to specialist clinics and the increased stress,

1 anxiety, expense and risk of physical harm from unnecessary ionizing radiation and  
2 treatments.' (England, PCP 7)  
3  
4

### 5 **Using information technology**

6

7  
8 This theme was about using electronic information and communication to improve diagnostic  
9 capability and enhance partnership working. Some PCPs thought that more decision support  
10 aids should be included in electronic health records:  
11  
12

13  
14  
15 'Automatic decision support/diagnostic support in the GP electronic information  
16 system based on symptoms.' (Netherlands, PCP10)  
17

18  
19  
20 'The 29 Norwegian guidelines regarding 'fast track referral for cancer' could be  
21 included into our electronic patient files as a real decision aid with extraction of clinical  
22 information for the referral.' (Norway, PCP3)  
23  
24  
25

26  
27  
28 Information technology could also be used to help identify those who would benefit from  
29 screening, and provide reminders relating to individual patients where needed:  
30  
31

32  
33 'Select specific age groups from healthcare databases and identify the individuals that  
34 haven't had the screening.' (Portugal, PCP11)  
35

36  
37  
38 'Using an automatic reminder system for cancer screening for each patient.' (Greece,  
39 PCP15)  
40  
41  
42

43  
44 Some PCPs were keen on the option to have 'virtual consultations' with specialists:  
45

46  
47 'Allow virtual consultations with specialists in specific subjects to validate malignancy  
48 diagnosis (radiologists/pulmonologists/gastroenterologists/surgeons, etc.) (Israel,  
49 PCP18)  
50  
51  
52

### 53 **Allocating funding to support timely diagnosis**

54

55  
56  
57 Adequate resources for primary care and targeted funding for investigations were frequently  
58 recommended by participants. This theme wove through the whole cancer diagnostic process.  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

An increase in primary care financing was considered to be necessary if PCPs were to improve access to care:

'By increasing resources in primary care in order to improve the access to care.'

(Finland, PCP34)

Adequate funds were also seen to be needed for screening and diagnostic tests:

'Increase funding of screening tests.' (Poland, PCP20)

'A higher budget for diagnostic tests, covering ... some higher costs related to the investigation and early diagnosis of cancer.' (Romania, PCP59)

In some countries, there was a need for an increase in the budget for diagnostic tests and referrals:

'Increase funding for cancer diagnostic tests (tumour markers, colonoscopy, gastroscopy, radiographs) - currently, the funding is insufficient.' (Poland, PCP29)

'Unlimited lab tests and unlimited referrals to specialist services if malignant conditions are suspected.' (Bulgaria, PCP11)

Funding limitations could be an issue for patients:

'Many patients refuse the investigations because of the costs (tumour markers, MRI, extra payment to the specialist doctor, ineffective collaboration between specialities).'  
(Romania, PCP12)

This could also affect the finances of the PCPs themselves:

'Ensure adequate financial support – at present there are penalties if the number of consultations exceeds the limit, even if the consultations are clinically indicated.'  
(Bulgaria, PCP25)

## Discussion

### Principal findings

In this primary care study, participants from twenty countries were able to use their experience situated in their own healthcare systems to provide a rich variety of suggestions for the improvements needed to allow more timely diagnosis of cancer. These covered the whole diagnostic pathway, from recommendations on how to help patients to present earlier with their symptoms, through continuing medical education that would help PCPs to recognise and act on symptoms that could be due to cancer, to improving communication and inter-professional partnership between and within primary and secondary care. Improving health system organisation and health policies is essential for achieving these goals. Facilitating patients' access to health care was also considered important, as was enabling fast and direct PCP access to diagnostic tests. Respondents saw funding allocation as an underlying component of most of these issues. They also identified a risk that reducing delays in cancer diagnosis in some patients could lead to overdiagnosis in others.

### Strengths and weaknesses of the study

This is the first trans-European study to explore PCPs' perceptions of how timeliness of cancer diagnosis can be improved, offering a unique insight into the operational and administrative challenges. This could be invaluable for the evaluation and revision of current healthcare policies and practices. Cancer diagnosis is a complex process and the diagnostic behaviour of PCPs working under the influences of their native health care systems is a key determinant. A key strength of our work is that we have gathered the views of PCPs from 20 countries on this process; our analysis examines systemic influences on PCP cancer diagnostic activity across Europe.

Variation in geography, health systems and levels of healthcare spending was provided by having four participating countries from each of the Central, Eastern, Northern, Southern and



1 Western European geographical areas. The sample size was large and diverse, with  
2 participants varying in terms years of clinical practice, gender, and site and size of practice.  
3  
4 The study successfully recruited participants in countries in which PCPs are  
5  
6 underrepresented in research.  
7

8  
9 The survey had only one, short question that related directly to our research question.  
10  
11 However, it may be that this format prompted participants to focus on writing down only  
12  
13 what, for them, was the most important point. Neither patients, secondary care nor other  
14  
15 primary care health professionals were included in the survey, and these groups may have  
16  
17 had other insights to offer. There is a risk that the translators and investigators  
18  
19 misunderstood some of the nuances of the twenty different languages, cultures and healthcare  
20  
21 organisations involved in this study. While themes were identified from responses from PCPs  
22  
23 in 20 European countries, not all of the themes identified will be equally relevant to each of  
24  
25 the participating countries.  
26  
27  
28  
29

30  
31 The data collection was completed in December 2016, and participating countries' health  
32  
33 systems will have continued to develop since then. However, each of the themes results from  
34  
35 PCPs' comments on healthcare is situated in a society and culture which changes very slowly,  
36  
37 as is also seen for implementation of new knowledge. The findings are therefore likely to  
38  
39 continue to be relevant.  
40  
41  
42

### 43 **Comparison with other studies**

44  
45  
46 Our findings map across to those of a survey of GPs in Ireland, which identified that barriers  
47  
48 to early cancer diagnosis included lack of direct GP access to diagnostic tests, difficulties with  
49  
50 referral to secondary care, poor clarity relating to cancer screening, unequal patient access to  
51  
52 secondary services, and a need for further training and guidelines<sup>39</sup>. GPs' views on the  
53  
54 importance of closer links between primary and secondary care were identified in that study,  
55  
56 and also in a United Kingdom (UK) study<sup>29</sup>. Our PCPs' call for improved patient education and  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

better access to diagnostic testing specialist care were also prioritised by GPs in another UK study <sup>40</sup>. Our findings map across to the findings from qualitative research on patient-perceived barriers to early presentation and diagnosis of cancer, which have identified the need for better access to services for patients <sup>41 42</sup> and better patient awareness of cancer symptoms <sup>42</sup> as key issues.

The need for healthcare systems to support PCPs' quick and easy access to investigations has been proposed before <sup>43</sup>. While investigation in primary care has been linked with later referral for specialist assessment, reducing the waiting time for tests would be expected to shorten the primary-care intervals associated with investigation use <sup>44</sup>. Despite this, another study found that some patients received a delayed cancer diagnosis, even when they had presented with typical cancer symptoms to a GP who had access to relevant diagnostic tests <sup>45</sup>.

### **Possible implications for clinicians and policymakers**

PCP respondents had specific recommendations on the changes that are needed to facilitate more timely diagnosis of cancer. Some recommendations, for instance health education campaigns and development of relevant guidelines, may need central direction, albeit with the input of PCPs. Others, for example improving the way PCP communicate with secondary care specialists, and PCPs' ability to access to cancer-specific tests, may need local agreement. Aspects such as PCPs' own communication skills, their own accessibility to patients and their continuing medical education, are more likely to be under PCPs' own control. However, a consideration of how funding is best reallocated is crucial if PCPs and their health systems are able to make these changes.

### **Unanswered questions and future research**

Further analysis is needed to help identify which recommendations are most relevant to different existing models of healthcare, for example as to whether some are particularly

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

relevant to systems in which the PCP has more of a 'gatekeeper' role, or to those in which PCP practises are large or smaller than average. A longitudinal study would give evidence on the trends on PCP opinions and how they are impacted by changes in health policies and public health initiatives. Research using interviews would give in-depth ideas on how changes resulting from the study findings could be implemented. A mixed-methods approach, comparing PCPs' views from different countries, would allow recommendations that are relevant to individual countries. In the study we have focused on the view of PCPs, as they have a key role in cancer diagnosis throughout Europe; however, the views of other stakeholders, such as patients and policy makers, are also important and should be included in future qualitative research.

There is a need to consider how to get the best balance between achieving early cancer diagnosis and minimising overdiagnosis of cancer. Our study gives the basic elements for the international primary care cancer research agenda, which would provide a knowledgebase for developing and improving cancer diagnosis and prognosis internationally.

## Conclusions

This research has identified key features that PCPs believe would be necessary to improve the timeliness of cancer diagnosis in their patients, and a need for re-allocation of health system funding to allow these to happen. Health systems need to facilitate earlier patient presentation through health education and better access to care, have well-educated clinicians with good access to investigations and better information technology, and adequate primary care cancer diagnostic pathway funding.

Many PCPs play a crucial role at the centre of their patients' care, and the breadth of their experience is reflected in their wide range of suggestions. This understanding should help to inform health service policy and research towards better cancer outcomes.

## List of abbreviations

CME	Continuing medical education
GP	General practitioner
PCP	Primary Care Physician
UK	United Kingdom

## Declarations

### Ethics approval

Ethical approval for the study was given by the University of Bath Research Ethics Approval Committee for Health (approval date: 24th November 2014; REACH reference number: EP 14/15 66). Other countries' study leads either achieved local ethical approval or gave statements that formal ethical approval was not needed in their jurisdictions.

### Competing interests

The authors declare that they have no competing interests.

### Funding

This study received no specific grant from any funding agency in the public, commercial or not-for-profit sectors. ALN is supported by the National Institute for Health Research (NIHR) Imperial Patient Safety Translation Research Centre, with infrastructure support provided by the NIHR Imperial Biomedical Research Centre (BRC).

### Data sharing statement

The Örenäs survey data that support the findings of this study are available from the corresponding author, M Harris, on reasonable request.

## Author contributions

1  
2  
3 K Buczkowski, M Brekke, N Buono, E Costiug, G-J Dinant, M Esteva, G Foreva, M Harris, R  
4  
5 Hoffman, E Jakob, T Koskela, M Marzo-Castillejo, P Murchie, AL Neves, DP Petek, J Sawicka-  
6  
7 Powierza, A Schneider, E Smyrnakis, S Streit, H Thulesius, P Vedsted and B Weltermann  
8  
9 participated in the study design, piloting and data collection. G Taylor participated in the  
10  
11 study design. S Harker coded some of the data. M Esteva and S Harker assisted in validated the  
12  
13 coding. M Esteva, M Harris, R Hoffman, T Koskela, AL Neves, D Petek and H Thulesius worked  
14  
15 together to agree the themes. M Harris had overall responsibility for the study design,  
16  
17 recruitment of local leads, analysis of data and interpretation of results. All authors  
18  
19 contributed to the writing and review of the manuscript and approved the final version.  
20  
21  
22  
23

## Acknowledgements

24  
25  
26  
27 The authors would like to thank all the PCPs who piloted the questionnaire and those who  
28  
29 completed the survey. They also thank the following non-author contributors: Isabelle Aubin-  
30  
31 Auger (Université Paris Diderot, Paris, France), Joseph Azuri (Tel Aviv University, Tel Aviv,  
32  
33 Israel), Svjetlana Gašparović Babić (The Teaching Institute of Public Health of Primorsko-  
34  
35 goranska County, Rijeka, Croatia) and Marija Petek Šter (University of Ljubljana, Ljubljana,  
36  
37 Slovenia).  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## References

1. Møller H, Linklater KM, Robinson D. A visual summary of the EUROCare-4 results: a UK perspective. *Br J Cancer* 2009;101(Suppl 2):S110-4.
2. EUROCare. EUROCare-5. In: Istituto Nazionale Tumori (Milan IaiSdSR, Italy), ed. Milan and Rome, 2014.
3. Maringe C, Walters S, Rachet B, et al. Stage at diagnosis and colorectal cancer survival in six high-income countries: a population-based study of patients diagnosed during 2000-2007. *Acta Oncol* 2013;52(5):919-32. doi: 10.3109/0284186X.2013.764008. Epub 2013 Apr 15.
4. Walters S, Maringe C, Coleman MP, et al. Lung cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK: a population-based study, 2004-2007. *Thorax* 2013;68(6):551-64. doi: 10.1136/thoraxjnl-2012-202297 [published Online First: 2013/02/13]
5. Richards M. The size of the prize for earlier diagnosis of cancer in England. *Br J Cancer* 2009;101 Suppl 2:S125-S29. doi: 10.1038/sj.bjc.6605402
6. Woods LM, Coleman MP, Lawrence G, et al. Evidence against the proposition that "UK cancer survival statistics are misleading": simulation study with National Cancer Registry data. *BMJ* 2011;342:d3399.(doi):10.1136/bmj.d3399.
7. Zahl PH, Jorgensen KJ, Gotzsche PC. Overestimated lead times in cancer screening has led to substantial underestimation of overdiagnosis. *Br J Cancer* 2013;109(7):2014-9. doi: 10.1038/bjc.2013.427. Epub 13 Aug 20.
8. Carter JL, Coletti RJ, Harris RP. Quantifying and monitoring overdiagnosis in cancer screening: a systematic review of methods. *BMJ* 2015;350:g7773.(doi):10.1136/bmj.g7773.
9. Peto J. Cancer epidemiology in the last century and the next decade. *Nature* 2001;411(6835):390-5. doi: 10.1038/35077256 [published Online First: 2001/05/18]
10. Popic T, Schneider SM. An East-West comparison of healthcare evaluations in Europe: Do institutions matter? *J Eur Soc Policy* 2018;28(5):517-34. doi: 10.1177/0958928717754294
11. Boscoe FP, Henry KA, Sherman RL, et al. The relationship between cancer incidence, stage and poverty in the United States. *Int J Cancer* 2016;139(3):607-12. doi: 10.1002/ijc.30087
12. Schrijvers C, Mackenbach J, Lutz J-M, et al. Deprivation and survival from breast cancer. *Br J Cancer* 1995;72(3):738. doi: 10.1038/bjc.1995.403
13. Mackie RM, Hole DJ. Incidence and thickness of primary tumours and survival of patients with cutaneous malignant melanoma in relation to socioeconomic status. *BMJ* 1996;312(7039):1125. doi: 10.1136/bmj.312.7039.1125
14. Butler J, Foot C, Bomb M, et al. The International Cancer Benchmarking Partnership: An international collaboration to inform cancer policy in Australia, Canada, Denmark, Norway, Sweden and the United Kingdom. *Health Policy* 2013;112(1):148-55.
15. Green T, Atkin K, Macleod U. Cancer detection in primary care: insights from general practitioners. *Br J Cancer* 2015;112:S41. doi: 10.1038/bjc.2015.41

16. Jacobsen MM, Silverstein SC, Quinn M, et al. Timeliness of access to lung cancer diagnosis and treatment: A scoping literature review. *Lung Cancer* 2017;112:156-64. doi: 10.1016/j.lungcan.2017.08.011 [published Online First: 2017/12/02]
17. McLaughlin JM, Anderson RT, Ferketich AK, et al. Effect on survival of longer intervals between confirmed diagnosis and treatment initiation among low-income women with breast cancer. *J Clin Oncol* 2012;30(36):4493-500. doi: 10.1200/jco.2012.39.7695 [published Online First: 2012/11/22]
18. Yun YH, Kim YA, Min YH, et al. The influence of hospital volume and surgical treatment delay on long-term survival after cancer surgery. *Ann Oncol* 2012;23(10):2731-7. doi: 10.1093/annonc/mds101 [published Online First: 2012/05/04]
19. Gobbi PG, Bergonzi M, Comelli M, et al. The prognostic role of time to diagnosis and presenting symptoms in patients with pancreatic cancer. *Cancer Epidemiol* 2013;37(2):186-90. doi: 10.1016/j.canep.2012.12.002 [published Online First: 2013/02/02]
20. Tørring ML, Frydenberg M, Hansen RP, et al. Evidence of increasing mortality with longer diagnostic intervals for five common cancers: a cohort study in primary care. *Eur J Cancer* 2013;49(9):2187-98. doi: 10.1016/j.ejca.2013.01.025 [published Online First: 2013/03/05]
21. Elit LM, O'Leary EM, Pond GR, et al. Impact of wait times on survival for women with uterine cancer. *J Clin Oncol* 2014;32(1):27-33. doi: 10.1200/jco.2013.51.3671 [published Online First: 2013/11/28]
22. Nanthamongkolkul K, Hanprasertpong J. Longer waiting times for early stage cervical cancer patients undergoing radical hysterectomy are associated with diminished long-term overall survival. *J Gynecol Oncol* 2015;26(4):262-9. doi: 10.3802/jgo.2015.26.4.262 [published Online First: 2015/09/26]
23. Neal R, Tharmanathan P, France B, et al. Is increased time to diagnosis and treatment in symptomatic cancer associated with poorer outcomes? Systematic review. *Br J Cancer* 2015;112 Suppl 1:S92-S107. doi: 10.1038/bjc.2015.48 [published Online First: 2015/03/04]
24. Olsson JK, Schultz EM, Gould MK. Timeliness of care in patients with lung cancer: a systematic review. *Thorax* 2009;64(9):749-56. doi: 10.1136/thx.2008.109330
25. Malmström M, Rasmussen BH, Bernhardson B-M, et al. It is important that the process goes quickly, isn't it?" A qualitative multi-country study of colorectal or lung cancer patients' narratives of the timeliness of diagnosis and quality of care. *Eur J Oncol Nurs* 2018;34:82-88. doi: 10.1016/j.ejon.2018.04.002
26. Foot C, Harrison T. How to improve cancer survival: explaining England's relatively poor rates. London: The King's Fund, 2011:30 January 2012.
27. Harris M, Frey P, Esteva M, et al. How health system factors influence referral decisions in patients that may have cancer: European symposium report. *J Cancer Res Ther* 2016;4(1):7-10. doi: 10.14312/2052-4994.2016-2
28. Johansen M-L, Holtedahl KA, Rudebeck CE. A doctor close at hand: How GPs view their role in cancer care. *Scand J Prim Health Care* 2010;28(4):249-55. doi: 10.3109/02813432.2010.526792
29. Adams E, Boulton M, Rose P, et al. Views of cancer care reviews in primary care: a qualitative study. *Br J Gen Pract* 2011;61(585):e173-e82. doi: 10.3399/bjgp11X567108

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
30. Mitchell GK, Burridge LH, Colquist SP, et al. General Practitioners' perceptions of their role in cancer care and factors which influence this role. *Health Soc Care Community* 2012;20(6):607-16. doi: 10.1111/j.1365-2524.2012.01075.x [published Online First: 2012/07/19]
  31. Perkins N, Coleman A, Wright M, et al. The 'added value' GPs bring to commissioning: a qualitative study in primary care. *Br J Gen Pract* 2014;64(628):e728-34. doi: 10.3399/bjgp14X682321
  32. Green T, Atkin K, Macleod U. GPs' perceptions and experiences of public awareness campaigns for cancer: a qualitative enquiry. *Health Expect* 2016;19(2):377-87. doi: 10.1111/hex.12362
  33. Harris M, Taylor G, Örenäs Research Group. How health system factors affect primary care practitioners' decisions to refer patients for further investigation: protocol for a pan-European ecological study. *BMC Health Serv Res* 2018;18(1):338. doi: 10.1186/s12913-018-3170-2
  34. Center for Aging in Diverse Communities. Guidelines for Translating Surveys in Cross-Cultural Research. San Francisco: University of California, 2007.
  35. Maneesriwongul W, Dixon JK. Instrument translation process: a methods review. *J Adv Nurs* 2004;48(2):175-86. doi: 10.1111/j.1365-2648.2004.03185.x [published Online First: 2004/09/17]
  36. Harris M, Vedsted P, Esteva M, et al. Identifying important health system factors that influence primary care practitioners' referrals for cancer suspicion: a European cross-sectional survey. *BMJ Open* 2018;8(9) doi: 10.1136/bmjopen-2018-022904
  37. Patton M. Qualitative Research & Evaluation Methods. Beverly Hills, CA: Sage 1990:177.
  38. Braun V, Clarke V. Using thematic analysis in psychology. *Qual Res Psychol* 2006;3(2):77-101. doi: 10.1191/1478088706qp063oa
  39. Daly H, Collins C. Barriers to early diagnosis of cancer in primary care: a needs assessment of GPs. *Ir Med J* 2007;100(10):624-6. [published Online First: 2008/02/19]
  40. Car LT, Papachristou N, Urch C, et al. Preventing delayed diagnosis of cancer: clinicians' views on main problems and solutions. *Journal of global health* 2016;6(2):020901. doi: 10.7189/jogh.06.020901 [published Online First: 2016/12/29]
  41. Ersin F, Bahar Z. Barriers and facilitating factors perceived in Turkish women's behaviors towards early cervical cancer detection: a qualitative approach. *Asian Pacific journal of cancer prevention : APJCP* 2013;14(9):4977-82. [published Online First: 2013/11/02]
  42. Cassim S, Chepulis L, Keenan R, et al. Patient and carer perceived barriers to early presentation and diagnosis of lung cancer: a systematic review. *BMC Cancer* 2019;19(1):25. doi: 10.1186/s12885-018-5169-9 [published Online First: 2019/01/10]
  43. Rubin G, Vedsted P, Emery J. Improving cancer outcomes: better access to diagnostics in primary care could be critical. *Br J Gen Pract* 2011;61(586):317-18. doi: 10.3399/bjgp11X572283
  44. Rubin GP, Saunders CL, Abel GA, et al. Impact of investigations in general practice on timeliness of referral for patients subsequently diagnosed with cancer: analysis of national primary care audit data. *Br J Cancer* 2015;112(4):676-87. doi: 10.1038/bjc.2014.634



45. Jiwa M, Meng X, O'Shea C, et al. How do general practitioners manage patients with cancer symptoms? A video-vignette study. *BMJ Open* 2015;5(9) doi: 10.1136/bmjopen-2015-008525

For peer review only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Table 1.** National distribution of PCPs who responded to the question 'How do you think the speed of diagnosis of cancer in primary care could be improved?'

Country	Number of PCPs who completed the survey	Number who answered the open-ended question (% of all survey completers)
Bulgaria	52	45 (86.5)
Croatia	56	42 (75.0)
Denmark	92	71 (77.2)
England	62	25 (40.3)
Finland	61	39 (63.9)
France	52	35 (67.3)
Germany	91	31 (34.1)
Greece	59	50 (84.7)
Israel	58	42 (72.4)
Italy	60	52 (86.7)
Netherlands	108	84 (77.8)
Norway	81	46 (56.8)
Poland	135	103 (76.3)
Portugal	59	46 (78.0)
Romania	146	132 (90.4)
Scotland	62	55 (88.7)

Slovenia	91	52 (57.1)
Spain	380	332 (87.4)
Sweden	68	55 (80.9)
Switzerland	60	15 (25.0)
Total	1,833	1,352 (73.8)

For peer review only

**Table 2.** Demographic distribution of PCPs who responded to the question 'How do you think the speed of diagnosis of cancer in primary care could be improved?'

Demographic	Number (%)
Gender	
Female	833 (61.6)
Male	513 (38.0)
Not stated	5 (0.4)
Years since graduation	
<10	192 (14.2)
10–19	356 (26.4)
20–29	416 (30.8)
30–39	336 (24.9)
40 or over	47 (3.5)
Not stated	4 (0.3)
Site of practice	
Urban	816 (60.4)
Rural	314 (23.2)
Island	25 (1.9)

Mixed	194 (14.4)
Not stated	2 (0.1)
Number of doctors in practice	
1-2	337 (24.9)
3-5	344 (25.5)
6-9	290 (21.5)
10 or more	374 (27.7)
Not stated	6 (0.4)

## Figure legends

**Figure 1.** *Diagrammatic representation of themes emerging from responses to the question:  
'How do you think the speed of diagnosis of cancer in primary care could be improved?'*

For peer review only




Figure 1. Diagrammatic representation of themes emerging from responses to the question: 'How do you think the speed of diagnosis of cancer in primary care could be improved?'

292x200mm (300 x 300 DPI)

## Supplementary file. Ethical and other approvals obtained in each Örenäs Research Group participating jurisdiction

	Date of Ethics Approval	Approvals obtained	Reference
Bulgaria	29 October 2015	Medical University Plovdiv Ethical Commission	P-7820
Croatia	16 December 2016	Nastavni Zovod Za Javno Zdravstvo	08-820-61/31-15
Denmark	7 May 2016	Danish Data Protection Agency; according to Danish law and the Central Denmark Region Committees on Health Research Ethics, approval by the National Committee on Health Research Ethics was not required as no biomedical intervention was performed.	2009-41-3471
Finland	16 November 2016	Academic Ethics Committee of the Tampere Region	16 November 2016
France	N/A	In France, research ethics approval was not required as no biomedical intervention was performed.	
Germany	15 January 2016	Ethik-Kommission Universität Duisberg-Essen	16-6747-BO
Greece	N/A	In Greece, research ethics approval was not required as no biomedical intervention was performed.	
Israel	N/A	In Israel, research ethics approval was not required as no biomedical intervention was performed.	
Italy	N/A	In Italy the approval of the ethical committee is not required when a study is neither an interventional nor an observational study on pharmacological treatment.	Decreto Legislativo n. 211 (24 giugno 2003)<2001/20/EC
Netherlands	27 June 2016	medisch-ethischetoetsingscommissie (METC) azM/UM Maastricht UMC+	METC 16-4-113
Norway	N/A	In Norway, research ethics approval was not required as no biomedical intervention was performed.	
Poland	28 January 2016	Komisja Bioetyczna Uniwersytetu Medycznego w Białymstoku	R_I_022/10/2016



1 2 3	Portugal	N/A	In Portugal, research ethics approval was not required as no biomedical intervention was performed.	
4 5 6 7	Romania	N/A	In Romania, research ethics approval was not required as no biomedical intervention was performed.	
8 9 10	Slovenia	8 December 2014	Komisija Republike Slovenije Medicinsko Etiko	KME 113/08/14
11 12 13 14 15 16	Spain	25 October 2015 23 Decmber 2015	Comissio d'Investigacio Govern de les Illes Balears Informe del Comite Etic d'Investigacio Clinica	Palma 27oct15 P15/159
17 18 19 20 21 22 23 24	Sweden	N/A	In Sweden, research ethics approval was not required as no biomedical intervention was performed. It does not fall under the law of research on human subjects to ask professionals about their work and how they perceive it.	
25 26 27 28 29 30 31	Switzerland	N/A	Swiss law on human research (Humanforschungsgesetz, HFG) does not require that an ethics committee approve collection and analysis of non-medical and anonymous data.	
32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60	United Kingdom	24 November 2014	Research Ethics Approval Committee for Health, University of Bath	EP 14/15 66

# Reporting checklist for qualitative study.

Based on the SRQR guidelines.

## Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the SRQR reporting guidelines, and cite them as:

O'Brien BC, Harris IB, Beckman TJ, Reed DA, Cook DA. Standards for reporting qualitative research: a synthesis of recommendations. *Acad Med.* 2014;89(9):1245-1251.

	Reporting Item	Page Number
	<a href="#">#1</a> Concise description of the nature and topic of the study identifying the study as qualitative or indicating the approach (e.g. ethnography, grounded theory) or data collection methods (e.g. interview, focus group) is recommended	1
	<a href="#">#2</a> Summary of the key elements of the study using the abstract format of the intended publication; typically includes background, purpose, methods, results and conclusions	4-5
Problem formulation	<a href="#">#3</a> Description and significance of the problem / phenomenon studied: review of relevant theory and empirical work; problem statement	7-8
Purpose or research question	<a href="#">#4</a> Purpose of the study and specific objectives or questions	8
Qualitative approach and research paradigm	<a href="#">#5</a> Qualitative approach (e.g. ethnography, grounded theory, case study, phenomenology, narrative research) and guiding theory if appropriate; identifying the research paradigm (e.g. postpositivist, constructivist / interpretivist) is also	9-10

recommended; rationale. The rationale should briefly discuss the justification for choosing that theory, approach, method or technique rather than other options available; the assumptions and limitations implicit in those choices and how those choices influence study conclusions and transferability. As appropriate the rationale for several items might be discussed together.

1			
2			
3			
4			
5			
6			
7			
8			
9			
10	Researcher characteristics	<a href="#">#6</a>	10-11
11	and reflexivity	Researchers' characteristics that may influence the research, including personal attributes, qualifications / experience, relationship with participants, assumptions and / or presuppositions; potential or actual interaction between researchers' characteristics and the research questions, approach, methods, results and / or transferability	
12			
13			
14			
15			
16			
17			
18			
19			
20	Context	<a href="#">#7</a>	9-10
21		Setting / site and salient contextual factors; rationale	
22	Sampling strategy	<a href="#">#8</a>	10
23		How and why research participants, documents, or events were selected; criteria for deciding when no further sampling was necessary (e.g. sampling saturation); rationale	
24			
25			
26			
27	Ethical issues pertaining	<a href="#">#9</a>	10; 24
28	to human subjects	Documentation of approval by an appropriate ethics review board and participant consent, or explanation for lack thereof; other confidentiality and data security issues	
29			
30			
31			
32			
33	Data collection methods	<a href="#">#10</a>	9-10
34		Types of data collected; details of data collection procedures including (as appropriate) start and stop dates of data collection and analysis, iterative process, triangulation of sources / methods, and modification of procedures in response to evolving study findings; rationale	
35			
36			
37			
38			
39			
40			
41	Data collection	<a href="#">#11</a>	9
42	instruments and	Description of instruments (e.g. interview guides, questionnaires) and devices (e.g. audio recorders) used for data collection; if / how the instruments(s) changed over the course of the study	
43	technologies		
44			
45			
46			
47			
48	Units of study	<a href="#">#12</a>	11
49		Number and relevant characteristics of participants, documents, or events included in the study; level of participation (could be reported in results)	
50			
51			
52			
53	Data processing	<a href="#">#13</a>	10
54		Methods for processing data prior to and during analysis, including transcription, data entry, data management and security, verification of data integrity, data coding, and anonymisation / deidentification of excerpts	
55			
56			
57			
58			
59			
60			

1	Data analysis	<a href="#">#14</a>	Process by which inferences, themes, etc. were identified and developed, including the researchers involved in data analysis; usually references a specific paradigm or approach; rationale	10
2				
3				
4				
5				
6	Techniques to enhance trustworthiness	<a href="#">#15</a>	Techniques to enhance trustworthiness and credibility of data analysis (e.g. member checking, audit trail, triangulation); rationale	10
7				
8				
9				
10				
11	Syntheses and interpretation	<a href="#">#16</a>	Main findings (e.g. interpretations, inferences, and themes); might include development of a theory or model, or integration with prior research or theory	11-19
12				
13				
14				
15				
16				
17	Links to empirical data	<a href="#">#17</a>	Evidence (e.g. quotes, field notes, text excerpts, photographs) to substantiate analytic findings	11-19
18				
19				
20				
21	Intergration with prior work, implications, transferability and contribution(s) to the field	<a href="#">#18</a>	Short summary of main findings; explanation of how findings and conclusions connect to, support, elaborate on, or challenge conclusions of earlier scholarship; discussion of scope of application / generalizability; identification of unique contributions(s) to scholarship in a discipline or field	19-21
22				
23				
24				
25				
26				
27				
28				
29	Limitations	<a href="#">#19</a>	Trustworthiness and limitations of findings	20
30				
31	Conflicts of interest	<a href="#">#20</a>	Potential sources of influence of perceived influence on study conduct and conclusions; how these were managed	24
32				
33				
34				
35	Funding	<a href="#">#21</a>	Sources of funding and other support; role of funders in data collection, interpretation and reporting	24
36				
37				
38				

39 The SRQR checklist is distributed with permission of Wolters Kluwer © 2014 by the Association of American  
 40 Medical Colleges. This checklist can be completed online using <https://www.goodreports.org/>, a tool made by  
 41 the [EQUATOR Network](#) in collaboration with [Penelope.ai](#)  
 42  
 43  
 44  
 45  
 46  
 47  
 48  
 49  
 50  
 51  
 52  
 53  
 54  
 55  
 56  
 57  
 58  
 59  
 60

# BMJ Open

## How European primary care practitioners think the timeliness of cancer diagnosis can be improved – a thematic analysis

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-030169.R2
Article Type:	Original research
Date Submitted by the Author:	17-Jul-2019
Complete List of Authors:	<p>Harris, Michael; University of Bath, Department for Health; University of Bern, Berner Institut für Hausarztmedizin (BIHAM)</p> <p>Thulesius, Hans; Lund University, Department of Clinical Sciences; Department of Research and Development</p> <p>Neves, Ana Luísa; Imperial College London, Institute of Global Health Innovation; University of Porto, CINTESIS (Centre for Health Technology and Services Research) and MEDCIDS (Department of Community Medicine, Information and Health Decision Sciences), Faculty of Medicine</p> <p>Harker, Sophie; University of Bath, Department for Health</p> <p>Koskela, Tuomas; Tampere University, Faculty of Medicine and Health Technology</p> <p>Petek, Davorina; Univerza v Ljubljani, Department of Family Medicine</p> <p>Hoffman, Robert; Tel Aviv University, Department of Family Medicine</p> <p>Brekke, Mette; University of Oslo, Department of General Practice and General Practice Research Unit</p> <p>Buczowski, Krzysztof; Nicolaus Copernicus University, Department of Family Medicine</p> <p>Buono, Nicola; SNAMID, Family medicine</p> <p>Costiug, Emiliana; Universitatea de Medicina si Farmacie Iuliu Hatieganu, Family Medicine Department</p> <p>Dinant, Geert-Jan; Maastricht University, Dept of General Practice</p> <p>Foreva, Gergana; Medical Center BROD</p> <p>Jakob, Eva; Centro de Saúde Sarria, Primary Health Centre</p> <p>Marzo, Mercè; Unitat de Suport a la Recerca Costa de Ponent, IDIAP</p> <p>Jordi Gol,</p> <p>Murchie, Peter; University of Aberdeen, Division of Applied Health Science</p> <p>Sawicka-Powierza, Jolanta; Uniwersytet Medyczny w Białymstoku, Department of Family Medicine</p> <p>Schneider, Antonius; Technical University of Munich, TUM School of Medicine, Institute of General Practice and Health Services Research</p> <p>Smyrnakis, Emmanouil; Aristotle University of Thessaloniki, Laboratory of Primary Health Care, General Practice and Health Services Research</p> <p>Streit, Sven; University of Bern, Berner Institut für Hausarztmedizin (BIHAM)</p> <p>Taylor, Gordon; University of Exeter, College of Medicine and Health</p> <p>Vedsted, Peter; Research Unit for General Practice, University of Aarhus</p> <p>Weltermann, Birgitta; University of Bonn, Institut für Hausarztmedizin</p> <p>Esteva, Magdalena; Gerencia Atencio Primaria de Mallorca, Unidad de</p>

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

	Investigación
<b>Primary Subject Heading</b> :	General practice / Family practice
<b>Secondary Subject Heading</b> :	Oncology, Qualitative research, Public health
<b>Keywords</b> :	Delivery of Health Care, Primary Health Care, General Practitioners, Cancer, Diagnosis, Consultation and Referral



# How European primary care practitioners think the timeliness of cancer diagnosis can be improved – a thematic analysis

Michael Harris <sup>1,2</sup> (corresponding author), michaelharris681@btinternet.com

Hans Thulesius <sup>3,4</sup>, hansthulesius@gmail.com

Ana Luísa Neves <sup>5,6</sup>, ana.luisa.neves@gmail.com

Sophie Harker <sup>1</sup>, sophie.888@btinternet.com

Tuomas Koskela <sup>7</sup>, tuomas.koskela@tuni.fi

Davorina Petek <sup>8</sup>, davorina.petek@gmail.com

Robert D. Hoffman <sup>9</sup>, hofman\_r@mac.org.il

Mette Brekke <sup>10</sup>, mette.brekke@medisin.uio.no

Krzysztof Buczkowski <sup>11</sup>, buczkowskik@cm.umk.pl

Nicola Buono <sup>12</sup>, buono.nicola2@gmail.com

Emiliana Costiug <sup>13</sup>, dr.costiug@gmail.com

Geert-Jan Dinant <sup>14</sup>, geertjan.dinant@maastrichtuniversity.nl

Gergana Foreva <sup>15</sup>, gerganaforeva@gmail.com

Eva Jacob <sup>16</sup>, eva.jacob.gonzalez@sergas.es

Mercè Marzo-Castillejo <sup>17</sup>, mmarzoc@gencat.cat

Peter Murchie <sup>18</sup>, p.murchie@abdn.ac.uk

Jolanta Sawicka-Powierza <sup>19</sup>, jolasawicka@gmail.com

Antonius Schneider <sup>20</sup>, antonius.schneider@tum.de

Emmanouil Smyrnakis <sup>21</sup>, smyrnak@auth.gr

Sven Streit <sup>2</sup>, sven.streit@biham.unibe.ch

Gordon Taylor <sup>22</sup>, g.j.taylor@exeter.ac.uk

Peter Vedsted <sup>23</sup>, p.vedsted@alm.au.dk

Birgitta Weltermann <sup>24</sup>, birgitta.weltermann@ukbonn.de

Magdalena Esteva <sup>25</sup>, mesteva@ibsalut.caib.es

<sup>1</sup> Department for Health, University of Bath, Claverton Down, Bath BA2 7AY, UK; telephone: +44 1761 241366; fax: none.

<sup>2</sup> Institute of Primary Health Care Bern (BIHAM), University of Bern, Bern, Switzerland

<sup>3</sup> Department of Clinical Sciences, Lund University, Malmö, Sweden

<sup>4</sup> Department of Research and Development, Region Kronoberg, Sweden

<sup>5</sup> Institute of Global Health Innovation, Imperial College, London, UK.

<sup>6</sup> CINTESIS (Centre for Health Technology and Services Research) and MEDCIDS (Department of Community Medicine, Information and Health Decision Sciences), Faculty of Medicine, University of Porto, Porto, Portugal

<sup>7</sup> Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.

<sup>8</sup> Department of Family Medicine, University of Ljubljana, Ljubljana, Slovenia.

<sup>9</sup> Department of Family Medicine, Tel Aviv University, Tel Aviv, Israel.

<sup>10</sup> Department of General Practice and General Practice Research Unit, University of Oslo, Oslo, Norway.

<sup>11</sup> Department of Family Medicine, Nicolaus Copernicus University, Toruń, Poland.

<sup>12</sup> Department of General Practice, National Society of Medical Education in General Practice (SNaMID), Caserta, Italy.



- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50
- <sup>13</sup> Family Medicine Department, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania.
- <sup>14</sup> Department of General Practice, Maastricht University, Maastricht, Netherlands.
- <sup>15</sup> Medical Center BROD, Plovdiv, Bulgaria
- <sup>16</sup> Primary Health Centre, Centro de Saúde Sarria, Sarria, Lugo, Spain.
- <sup>17</sup> Unitat de Suport a la Recerca, IDIAP Jordi Gol, Institut Català de la Salut, Barcelona, Spain.
- <sup>18</sup> Division of Applied Health Sciences - Academic Primary Care, University of Aberdeen, Aberdeen, UK.
- <sup>19</sup> Department of Family Medicine, Medical University of Bialystok, Bialystok, Poland.
- <sup>20</sup> TUM School of Medicine, Institute of General Practice and Health Services Research, Technical University of Munich, Munich, Germany.
- <sup>21</sup> Laboratory of Primary Health Care, General Practice and Health Services Research, Aristotle University of Thessaloniki, Thessaloniki, Greece.
- <sup>22</sup> College of Medicine and Health, University of Exeter, Exeter, UK.
- <sup>23</sup> The Research Unit for General Practice, Aarhus University, Aarhus, Denmark.
- <sup>24</sup> Institut für Hausarztmedizin, University of Bonn, Bonn, Germany.
- <sup>25</sup> Research Unit, Majorca Primary Health Care Department, Balearic Islands Health Research Institute (IdISBa), Preventive Activities and Health Promotion Network, Carlos III Institute of Health (RedIAPP-RETICS), Palma, Spain.

51  
52  
53

### Keywords

54 Delivery of Health Care; Primary Health Care; General Practitioners; Cancer; Diagnosis;  
55  
56 Consultation and Referral.  
57  
58  
59  
60

**Word count**

3,182 (excluding data/quotes)

**Abstract****Background**

National European cancer survival rates vary widely. Prolonged diagnostic intervals are thought to be a key factor in explaining these variations. Primary Care Practitioners (PCPs) frequently play a crucial role during initial cancer diagnosis; their knowledge could be used to improve the planning of more effective approaches to earlier cancer diagnosis.

**Objectives**

This study sought the views of PCPs from across Europe on how they thought the timeliness of cancer diagnosis could be improved.

**Design**

In an online survey, a final open-ended question asked PCPs how they thought the speed of diagnosis of cancer in primary care could be improved. Thematic analysis was used to analyse the data.

**Setting**

A primary care study, with participating centres in twenty European countries.

**Participants**

A total of 1,352 PCPs answered the final survey question, with a median of 48 per country.

**Results**

The main themes identified were: patient-related factors, including health education; care provider-related factors, including continuing medical education; improving communication

1 and inter-professional partnership, particularly between primary and secondary care; factors  
2 relating to health system organization and policies, including improving access to health care;  
3  
4 easier primary care access to diagnostic tests; and use of information technology. Re-  
5  
6 allocation of funding to support timely diagnosis was seen as an issue affecting all of these.  
7  
8  
9

## 10 **Conclusions**

11  
12 To achieve more timely cancer diagnosis, health systems need to facilitate earlier patient  
13 presentation through education and better access to care, have well-educated clinicians with  
14  
15 good access to investigations and better information technology, and adequate primary care  
16  
17 cancer diagnostic pathway funding.  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Article Summary

### Strengths and limitations of this study

- We recruited PCPs from 20 European countries, four countries from each of the Northern, Southern, Eastern, Western and Central European geographical areas, to provide variation in geography, health systems and levels of healthcare spending.
- The recruitment method allowed participation of physicians in countries in which PCPs are underrepresented in research.
- The survey had only one question that related directly to PCPs' views on the timeliness of cancer diagnosis.
- Neither patients, secondary care nor other primary care health professionals were included in the survey, and these groups may have had other insights to offer.

## Introduction

1  
2  
3 Cancer survival rates vary widely in Europe <sup>1</sup>, leading to considerable additional mortality in  
4  
5 some countries. Data from the European Cancer Registry-based Study on Survival and Care of  
6  
7 Cancer Patients (EUROCARE-5) show that the national 1-year relative survival rates for all  
8  
9 cancer sites vary from 58.2% to 81.1% <sup>2</sup>. Poorer 1-year relative survival is thought to be  
10  
11 indicative of diagnostic delay <sup>3 4</sup> and more advanced disease at diagnosis <sup>5 6</sup>, although it can be  
12  
13 affected by differences in registration, as well as overdiagnosis and lead-time biases <sup>7 8</sup>. There  
14  
15 may also be geographical differences in incidence of cancers that have a poorer prognosis <sup>9</sup>, as  
16  
17 well as national variations in access to effective cancer treatment <sup>10</sup>, and in levels of poverty,  
18  
19 which in itself has been linked with more advanced disease stage at diagnosis <sup>11-13</sup>. More  
20  
21 advanced cancers are more difficult to treat successfully <sup>14</sup> and, for many cancers, the stage of  
22  
23 disease at diagnosis is related to survival <sup>15 16</sup>. There is considerable evidence that longer time  
24  
25 to diagnosis and treatment has an adverse impact on cancer mortality <sup>17-23</sup>. Timely care also  
26  
27 adds to patients' quality of life and emotional well-being <sup>24</sup>. In addition, patients' descriptions  
28  
29 of the quality of their care are closely related to the speed of their diagnosis and treatment;  
30  
31 this is because they are concerned that longer waits might allow time for their cancers to  
32  
33 grow <sup>25</sup>.

34  
35  
36  
37  
38  
39  
40  
41 Timely diagnosis of cancer has therefore been an important aim of healthcare providers  
42  
43 across Europe <sup>25</sup>. However, the challenge in deciding where and how to achieve this is  
44  
45 substantial <sup>26</sup>. In countries where a comparatively low 1-year cancer survival suggests that  
46  
47 late diagnosis may be a major factor, it is uncertain whether this is due to patients presenting  
48  
49 later to health-care, whether they are not being referred quickly enough by those in primary  
50  
51 care, or whether they are not being investigated and managed efficiently in secondary care <sup>14</sup>.  
52  
53 This may be a particular problem where patients with cancer present without red-flag  
54  
55 symptoms, as how their primary care practitioners (PCPs) act depends on how their health  
56  
57 systems are organised <sup>27</sup>.  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Doctors and their patients recognise that general practitioners (GPs) and other PCPs have a key role in cancer detection <sup>28-30</sup>. It has been suggested that PCPs' knowledge of their patient populations can be used to improve health service design <sup>31</sup> and the planning for more effective approaches to earlier cancer recognition and referral <sup>32</sup>. There has been a call for research in this field <sup>15</sup>; although PCPs' experience of their own health systems could potentially help to improve the planning of more effective approaches to earlier cancer recognition and referral, their perceptions have not been previously evaluated.

The aim of this study was to elicit the views of GPs and other PCPs from across Europe on how they thought the timeliness of cancer diagnosis could be improved.

## Methods and design

### Design

Between November 2015 and December 2016, we performed an online survey of PCPs in 20 European countries. The methodology of the study is described in our published protocol paper <sup>33</sup>.

### Development of the questionnaire

The Örenäs Research Group is a European group of primary care researchers that studies the primary care factors that relate to cancer survival. After a literature review, Örenäs Research Group investigators developed a questionnaire designed to elicit PCPs' referral decisions on patients that could have cancer, and their degree of agreement with items relating to health system aspects that could affect their decision to refer patients with potential cancer symptoms for further investigation. The final, open-ended question asked: 'How do you think the speed of diagnosis of cancer in primary care could be improved?' The answers to this question are used in this analysis.

The questionnaire was piloted twice by PCPs in 16 Örenäs Research Group centres. No changes were made to the final, open-ended question after either of the piloting stages. Örenäs Research Group leads arranged for translations of the questionnaire into their local languages where these were not English, a total of 19 translations from the original English. Translation, validation by back-translation to assess semantic and conceptual equivalence, and cultural adaptation <sup>34</sup> of the survey were done in a standardised way <sup>35</sup> and are described elsewhere <sup>36</sup>. The questionnaires were put online using SurveyMonkey (SurveyMonkey, California, USA).

## Participants and recruitment

1  
2 The study was conducted in 25 Örenäs Research Group centres in 20 countries across Europe:  
3  
4 Bulgaria, Croatia, Denmark, England, Finland, France, Germany, Greece, Israel, Italy,  
5  
6 Netherlands, Norway, Poland, Portugal, Romania, Scotland, Slovenia, Spain, Sweden and  
7  
8 Switzerland. Local study leads were asked to either gain ethical approval or obtain a  
9  
10 statement that formal ethical approval was not needed in their jurisdiction (see  
11  
12 supplementary file).  
13  
14  
15

16  
17 Criterion sampling was used<sup>37</sup>, with subjects being eligible for the survey if they were doctors  
18  
19 working mainly in primary care. These doctors, referred to collectively here as 'Primary Care  
20  
21 Practitioners', consisted of GPs as well as other doctors who had specialist training but  
22  
23 worked in the community and could be accessed directly by patients without referral.  
24  
25

26  
27 Each Örenäs Research Group local lead was asked to email a survey invitation to the PCPs in  
28  
29 their local health district, and to recruit at least 50 participants, with no maximum limit. This  
30  
31 allowed recruitment of a varied sample with regards to gender, years since graduation, site of  
32  
33 practice (urban, rural, remote), and size of practice. Consent was implied by agreeing to take  
34  
35 part in the survey.  
36  
37  
38

## Data analysis

39  
40  
41  
42 Local Örenäs Research Group leads translated the responses from their own languages into  
43  
44 English and sent them to MH, who asked them for more information where the translation or  
45  
46 context was unclear.  
47  
48

49  
50 We used inductive thematic analysis<sup>38</sup>, an approach in which codes and themes are suggested  
51  
52 by the data rather than by a theoretical framework. The phases of analysis included coding,  
53  
54 followed by the identification and clustering of themes and sub-themes, and the production of  
55  
56 a descriptive thematic summary. Two researchers (MH and SH) independently coded the data  
57  
58 from three countries and compared their analyses for inconsistencies and agreement. MH  
59  
60



1 then coded the data from the other countries. Team members from seven participating  
2 countries (ME, MH, RH, TK, ALN, DP, HT, all PCPs) then independently considered themes and  
3 sub-themes, discussed these and came to a consensus over the course of two meetings. The  
4 themes and sub-themes were grouped to construct an interpretative narrative across the  
5 dataset and depicted diagrammatically. Apart from SH, a Masters psychology student, all  
6 authors involved in the coding and thematic analysis were experienced general practitioners  
7 who were also active in primary care research.  
8  
9  
10  
11  
12  
13  
14  
15

## 16 **Patient and public involvement**

17  
18  
19 There was no patient or public involvement in this study.  
20  
21  
22

## 23 **Results**

24  
25  
26 A total of 1,833 PCPs completed the full questionnaire, with a median response rate per  
27 country of 24.8% (range 7.1% to 65.6%). All participating centres received at least 50  
28 responses, with a median of 61 PCPs per country. In all, 1,352 PCPs (73.8% of completers)  
29 gave an answer to the final, open-ended survey question 'How could the speed of diagnosis of  
30 cancer in primary care could be improved?', with a median of 48 per country (Table 1). To  
31 reduce the risk of bias from countries with larger numbers of respondents, we coded a  
32 maximum of 100 respondents' comments, randomly sampled, per country. The demographic  
33 distributions of the PCPs answering this final survey question are shown in Table 2. Towards  
34 the end of the analysis, no new themes emerged.  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47

48 We identified four main themes organising the content of the responses to the final survey  
49 question: patient-related factors, care provider-related features, improving communication  
50 and inter-professional partnership, and aspects of health system organisation and health  
51 policies. Two structural facets transcended the four themes: accessing diagnostic tests and  
52 using information technology. The issue of allocating funding to support timely diagnosis fed  
53 into all the other themes. The themes are shown diagrammatically in Figure 1. Themes and  
54  
55  
56  
57  
58  
59  
60

subthemes are described below, with participant quotations identified by country and a participant number.

**(Place Figure 1 here)**

### **Patient-related factors**

This theme included ideas on education and training to improve patient knowledge. Many PCPs advocated the use of health education and media campaigns to improve patient awareness of alarm symptoms and signs:

‘By giving patients better information about when to go to a doctor - reduce patient delay.’ (Denmark, PCP69)

‘Improve health literacy of patients regarding the detection of early symptoms that might indicate oncological disease.’ (Portugal, PCP37)

Targeting advice on cancer risks was also considered important:

‘Informing patients about cancer risks related to their age groups.’ (Italy, PCP28)

However, public health messages could be seen as unworkable:

‘Stop public campaigns telling everyone with a particular symptom they need e.g. a chest X-ray after 3 weeks of cough – inappropriately blocking the service.’ (Scotland, PCP16)

### **Care provider-related factors**

PCPs had suggestions on how to improve their own knowledge and that of other caregivers, by both increasing the amount of the training and improving the teaching content. Improving the training of PCPs and other health care professionals was considered by many respondents to be important:

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

'By educating health care professionals. When to suspect and when to do further tests?'

(Finland, PCP33)

'CME [continuing medical education] on early signs and up-to-date investigation processes.' (Sweden, PCP52)

Alertness in their role was also considered key:

'Often the presence of alarm signs is too late ... Be alert and listen to the patients.'  
(Spain, PCP46)

Primary care doctors also need to be aware of the relevant clinical pathways:

'Training of GPs ... taking into account the entire pathway from symptom to diagnosis.'  
(Poland, PCP17)

PCPs thought it important that cancer screening and referral guidelines should be clear, and that they themselves should be involved in designing them.

'Clear guidelines regarding cancer alarm signs and referral indications.' (Finland, PCP37)

'GPs who design guidelines together with specialists.' (Sweden, PCP21)

### **Improving communication and inter-professional partnership**

Patient-PCP communication improvements and enhancements to inter-professional partnerships were frequently suggested by the PCP respondents. Improving communication with patients was considered important, though this implied having longer consultations:

'GPs should pay more attention when they speak to patients.' (Italy, PCP26)

'Longer consultations to allow more thorough assessment without pressure of time.'  
(Scotland, PCP5)

Improving the interaction within the practice team could also be helpful:

1 'Discussion in the team about recent referrals so the team benchmarks itself.' (England,  
2 PCP22)

3  
4 'A lot can be learnt from colleagues' experiences of missed diagnoses.' (Netherlands,  
5 PCP40)  
6  
7  
8  
9

10 Improving partnership between PCPs and other primary health care professionals, for  
11 example nurses and health-care assistants, with adequate training, was also considered  
12 important:  
13  
14  
15

16  
17 'Involve the nurses in gathering the patient's medical history.' (Poland, PCP20)  
18

19  
20 'Good training of health-care assistant to identify risk symptoms.' (Norway, PCP1)  
21  
22

23 Improving the relationship between primary and secondary care doctors, with easier and  
24 reliable communication between the two, was highlighted:  
25  
26  
27

28 'Easy communication with specialists (and, in my case, preferably email contact).'  
29

30 (Netherlands, PCP85)  
31  
32

33 'It is essential to establish a communication channel between primary health care and  
34 specialist health care so that critical patients would not get lost in the system.' (Croatia,  
35 PCP36)  
36  
37  
38  
39  
40

41 Joint working with public health departments was also considered valuable:  
42  
43

44 'With the cooperation between the National Institute of Public Health and family  
45 medicine specialists, who know their patients best.' (Croatia, PCP38)  
46  
47  
48

49 Many doctors commented on the importance of continuity of care:  
50  
51

52 'Knowing your patient well. Consequently, not having three different GPs for one  
53 patient.' (Netherlands, PCP69)  
54  
55  
56  
57  
58  
59  
60

## Strengthening system organisation and improving health policy

Strengthening how health systems are organised and implementing health policies that allow timely cancer diagnosis were key recommendations from many PCPs. Enhancing patient access to primary care, particularly for vulnerable or more remote groups, was considered important by some:

‘Shorter queues to GP appointment in order to start assessments without delay.’

(Finland, PCP33)

‘In some places (rural, inland) inaccessibility to MCDTs [screening examinations] can be an obstacle.’ Portugal, PCP43)

Practical steps to improve access to secondary care were also seen as key, particularly those relating to costs to the patient:

‘Access to specialists must be cheaper.’ (Romania, PCP99)

‘Patient friendly hospital services - so that the appointments are not too stressful or expensive (travel and parking).’ (England, PCP19)

Many PCPs commented on the need for better working conditions, a larger workforce, a reduced workload and less bureaucracy:

‘A sufficient number of healthcare professionals so that there is not too much workload for a few.’ (Croatia, PCP5)

‘Reduction of the workload at the family medicine doctor office.’ (Croatia, PCP31)

‘By decreasing bureaucracy! So we will have more time for a real consultation!’

(Romania, PCP49)

The adoption of financial incentives schemes was also suggested:

‘Allocating additional financial resources and stimulating the GP in this direction.’

(Romania, PCP78)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

'Financial incentives for preventative care of most common malignant conditions.'

(Bulgaria, PCP4)

PCPs felt that guidelines and protocols needed to be clear and relevant to them:

'Clear guidelines regarding cancer alarm signs and referral indications.' (Finland,

PCP37)

'By developing a more specific GP protocol for the various types of cancer.'

(Netherlands, PCP51)

Fast-track systems for patients with cancer were requested by many respondents:

'Create a fast-track unit for patients with high cancer suspicion.' (Spain, PCP51)

'Preferential appointments for cases with cancer suspicion in all hospital specialities.'

(Spain, PCP6)

In countries where fast-track systems already existed, these were seen as a success:

'Cancer diagnostics have priority in the Norwegian health care system since fast track referral was introduced last year. Functions well.' (Norway, PCP5)

'I actually think that the introduction of the "2-week wait" urgent referral system has greatly improved the speed of diagnosis for those with obvious red flag symptoms.'

(England, PCP11)

Some PCPs felt that there should be more uptake of national screening programmes:

'Encourage patients to use existing prevention programmes.' (Germany, PCP7)

'All physicians should adhere to screening guidelines.' (Switzerland, PCP8)

## Accessing diagnostic tests

This theme suggesting improvements to diagnostic structures dealt mainly with easier and quicker access to testing. Easier PCP access to diagnostic testing was cited by many respondents:

‘Increasing the range of diagnostics available; also making them easier to refer for.’

(Netherlands, PCP79)

‘Facilitating family doctors to request tests and investigations that he/she considers necessary for the diagnosis.’ (Spain, PCP39)

Many felt that they should have direct access to cancer-specific testing:

‘GPs should be able to recommend any investigation without reference to other specialist doctors.’ (Romania, PCP44)

‘Give GPs the ability to refer patients to more diagnostic tests e.g. CT, tumour markers.’

(Poland, PCP26)

The speed of access to diagnostic tests was also seen as key:

‘Faster access/fast track to imaging diagnostics could help us exclude a number of cases and so could relieve specialist services.’ (Norway, PCP18)

‘Reduction of the delay in getting special tests.’ (France, PCP 2)

However, some PCPs were worried that the increase in investigation of patients needed to diagnose cancers earlier could also lead to overdiagnosis and overtreatment:

‘Cancer diagnostics are a difficult balancing act between under- and overdiagnosis.

Faster cancer diagnostics will also give more overdiagnosis.’ (Norway, PCP 31)

‘Depends on the type of cancer, but there is a trade-off between diagnosing a few cancers earlier by referring lots more patients to specialist clinics and the increased stress,

1 anxiety, expense and risk of physical harm from unnecessary ionizing radiation and  
2 treatments.' (England, PCP 7)  
3  
4

### 5 **Using information technology**

6

7  
8 This theme was about using electronic information and communication to improve diagnostic  
9 capability and enhance partnership working. Some PCPs thought that more decision support  
10 aids should be included in electronic health records:  
11  
12

13  
14  
15 'Automatic decision support/diagnostic support in the GP electronic information  
16 system based on symptoms.' (Netherlands, PCP10)  
17

18  
19  
20 'The 29 Norwegian guidelines regarding 'fast track referral for cancer' could be  
21 included into our electronic patient files as a real decision aid with extraction of clinical  
22 information for the referral.' (Norway, PCP3)  
23  
24  
25

26  
27  
28 Information technology could also be used to help identify those who would benefit from  
29 screening, and provide reminders relating to individual patients where needed:  
30  
31

32  
33 'Select specific age groups from healthcare databases and identify the individuals that  
34 haven't had the screening.' (Portugal, PCP11)  
35

36  
37  
38 'Using an automatic reminder system for cancer screening for each patient.' (Greece,  
39 PCP15)  
40  
41  
42

43  
44 Some PCPs were keen on the option to have 'virtual consultations' with specialists:  
45

46  
47 'Allow virtual consultations with specialists in specific subjects to validate malignancy  
48 diagnosis (radiologists/pulmonologists/gastroenterologists/surgeons, etc.) (Israel,  
49 PCP18)  
50  
51  
52

### 53 **Allocating funding to support timely diagnosis**

54

55  
56  
57 Adequate resources for primary care and targeted funding for investigations were frequently  
58 recommended by participants. This theme wove through the whole cancer diagnostic process.  
59  
60



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

An increase in primary care financing was considered to be necessary if PCPs were to improve access to care:

'By increasing resources in primary care in order to improve the access to care.'

(Finland, PCP34)

Adequate funds were also seen to be needed for screening and diagnostic tests:

'Increase funding of screening tests.' (Poland, PCP20)

'A higher budget for diagnostic tests, covering ... some higher costs related to the investigation and early diagnosis of cancer.' (Romania, PCP59)

In some countries, there was a need for an increase in the budget for diagnostic tests and referrals:

'Increase funding for cancer diagnostic tests (tumour markers, colonoscopy, gastroscopy, radiographs) - currently, the funding is insufficient.' (Poland, PCP29)

'Unlimited lab tests and unlimited referrals to specialist services if malignant conditions are suspected.' (Bulgaria, PCP11)

Funding limitations could be an issue for patients:

'Many patients refuse the investigations because of the costs (tumour markers, MRI, extra payment to the specialist doctor, ineffective collaboration between specialities).'  
(Romania, PCP12)

This could also affect the finances of the PCPs themselves:

'Ensure adequate financial support – at present there are penalties if the number of consultations exceeds the limit, even if the consultations are clinically indicated.'  
(Bulgaria, PCP25)

## Discussion

### Principal findings

In this primary care study, participants from twenty countries were able to use their experience situated in their own healthcare systems to provide a rich variety of suggestions for the improvements needed to allow more timely diagnosis of cancer. These covered the whole diagnostic pathway, from recommendations on how to help patients to present earlier with their symptoms, through continuing medical education that would help PCPs to recognise and act on symptoms that could be due to cancer, to improving communication and inter-professional partnership between and within primary and secondary care. Improving health system organisation and health policies is essential for achieving these goals. Facilitating patients' access to health care was also considered important, as was enabling fast and direct PCP access to diagnostic tests. Respondents saw funding allocation as an underlying component of most of these issues. They also identified a risk that reducing delays in cancer diagnosis in some patients could lead to overdiagnosis in others.

### Strengths and weaknesses of the study

This is the first trans-European study to explore PCPs' perceptions of how timeliness of cancer diagnosis can be improved, offering a unique insight into the operational and administrative challenges. This could be invaluable for the evaluation and revision of current healthcare policies and practices. Cancer diagnosis is a complex process and the diagnostic behaviour of PCPs working under the influences of their native health care systems is a key determinant. A key strength of our work is that we have gathered the views of PCPs from 20 countries on this process; our analysis examines systemic influences on PCP cancer diagnostic activity across Europe.

Variation in geography, health systems and levels of healthcare spending was provided by having four participating countries from each of the Central, Eastern, Northern, Southern and

1 Western European geographical areas. The sample size was large and diverse, with  
2 participants varying in terms years of clinical practice, gender, and site and size of practice.  
3  
4 The study successfully recruited participants in countries in which PCPs are  
5  
6 underrepresented in research.  
7

8  
9 The survey had only one, short question that related directly to our research question.  
10  
11 However, it may be that this format prompted participants to focus on writing down only  
12  
13 what, for them, was the most important point. Neither patients, secondary care nor other  
14  
15 primary care health professionals were included in the survey, and these groups may have  
16  
17 had other insights to offer. There is a risk that the translators and investigators  
18  
19 misunderstood some of the nuances of the twenty different languages, cultures and healthcare  
20  
21 organisations involved in this study. While themes were identified from responses from PCPs  
22  
23 in 20 European countries, not all of the themes identified will be equally relevant to each of  
24  
25 the participating countries.  
26  
27  
28  
29

30  
31 The data collection was completed in December 2016, and participating countries' health  
32  
33 systems will have continued to develop since then. However, each of the themes results from  
34  
35 PCPs' comments on healthcare is situated in a society and culture which changes very slowly,  
36  
37 as is also seen for implementation of new knowledge. The findings are therefore likely to  
38  
39 continue to be relevant.  
40  
41  
42

### 43 **Comparison with other studies**

44  
45  
46 Our findings reflect those of a survey of GPs in Ireland, which identified that barriers to early  
47  
48 cancer diagnosis included lack of direct GP access to diagnostic tests, difficulties with referral  
49  
50 to secondary care, poor clarity relating to cancer screening, unequal patient access to  
51  
52 secondary services, and a need for further training and guidelines<sup>39</sup>. GPs' views on the  
53  
54 importance of closer links between primary and secondary care were identified in that and  
55  
56 other studies<sup>29 30</sup>. Our PCPs' call for improved patient education and better access to  
57  
58  
59  
60

1 diagnostic testing specialist care were also prioritised by GPs in another UK study <sup>40</sup>. Our  
2 findings map across to the findings from qualitative research on patient-perceived barriers to  
3 early presentation and diagnosis of cancer, which have identified the need for better access to  
4 services for patients <sup>41 42</sup> and better patient awareness of cancer symptoms <sup>42</sup> as key issues.  
5  
6 Our PCPs' call for an improved partnership with other primary health care professionals is  
7 one that has been successfully implemented before, though not specifically in relation to  
8 cancer diagnosis <sup>43</sup>. Their recommendation for better cancer awareness among primary care  
9 staff is confirmed by evidence from other research that there is a need for this <sup>44</sup>.

10  
11  
12  
13  
14  
15  
16  
17  
18  
19 GPs in other studies have identified issues that were not raised by PCPs in our study, including  
20 the perception that late presentation of cancer symptoms often relates to patients' socio-  
21 economic and socio-cultural circumstances <sup>15 30</sup>, a concern that fragmentation of health  
22 services adversely affects timeliness of cancer diagnosis <sup>15 45</sup>, and a need for mentoring of  
23 doctors unfamiliar with their health systems <sup>30</sup>.

24  
25  
26  
27  
28  
29  
30  
31 The need for healthcare systems to support PCPs' quick and easy access to investigations has  
32 been proposed before <sup>46</sup>. While investigation in primary care has been linked with later  
33 referral for specialist assessment, reducing the waiting time for tests would be expected to  
34 shorten the primary-care intervals associated with investigation use <sup>47</sup>. Despite this, another  
35 study found that some patients received a delayed cancer diagnosis, even when they had  
36 presented with typical cancer symptoms to a GP who had access to relevant diagnostic tests  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

### **Possible implications for clinicians and policymakers**

PCP respondents had specific recommendations on the changes that are needed to facilitate more timely diagnosis of cancer. Some recommendations, for instance health education campaigns and development of relevant guidelines, may need central direction, albeit with the input of PCPs. Others, for example improving the way PCP communicate with secondary care

specialists, and PCPs' ability to access to cancer-specific tests, may need local agreement.

Aspects such as PCPs' own communication skills, their own accessibility to patients and their continuing medical education, are more likely to be under PCPs' own control. However, a consideration of how funding is best reallocated is crucial if PCPs and their health systems are able to make these changes.

### **Unanswered questions and future research**

Further analysis is needed to help identify which recommendations are most relevant to different existing models of healthcare, for example as to whether some are particularly relevant to systems in which the PCP has more of a 'gatekeeper' role, or to those in which PCP practises are large or smaller than average. A longitudinal study would give evidence on the trends on PCP opinions and how they are impacted by changes in health policies and public health initiatives. Research using interviews would give in-depth ideas on how changes resulting from the study findings could be implemented. A mixed-methods approach, comparing PCPs' views from different countries, would allow recommendations that are relevant to individual countries. In the study we have focused on the view of PCPs, as they have a key role in cancer diagnosis throughout Europe; however, the views of other stakeholders, such as patients and policy makers, are also important and should be included in future qualitative research.

There is a need to consider how to get the best balance between achieving early cancer diagnosis and minimising overdiagnosis of cancer. Our study gives the basic elements for the international primary care cancer research agenda, which would provide a knowledgebase for developing and improving cancer diagnosis and prognosis internationally.

## Conclusions

This research has identified key features that PCPs believe would be necessary to improve the timeliness of cancer diagnosis in their patients, and a need for re-allocation of health system funding to allow these to happen. Health systems need to facilitate earlier patient presentation through health education and better access to care, have well-educated clinicians with good access to investigations and better information technology, and adequate primary care cancer diagnostic pathway funding.

Many PCPs play a crucial role at the centre of their patients' care, and the breadth of their experience is reflected in their wide range of suggestions. This understanding should help to inform health service policy and research towards better cancer outcomes.

## List of abbreviations

CME Continuing medical education

GP General practitioner

PCP Primary Care Physician

UK United Kingdom

## Declarations

### Ethics approval

Ethical approval for the study was given by the University of Bath Research Ethics Approval Committee for Health (approval date: 24th November 2014; REACH reference number: EP 14/15 66). Other countries' study leads either achieved local ethical approval or gave statements that formal ethical approval was not needed in their jurisdictions.

## Competing interests

The authors declare that they have no competing interests.

## Funding

This study received no specific grant from any funding agency in the public, commercial or not-for-profit sectors. ALN is supported by the National Institute for Health Research (NIHR) Imperial Patient Safety Translation Research Centre, with infrastructure support provided by the NIHR Imperial Biomedical Research Centre (BRC).

## Data sharing statement

The Örenäs survey data that support the findings of this study are available from the corresponding author, M Harris, on reasonable request.

## Author contributions

K Buczkowski, M Brekke, N Buono, E Costiug, G-J Dinant, M Esteva, G Foreva, E Jacob, M Harris, R Hoffman, E Jakob, T Koskela, M Marzo-Castillejo, P Murchie, AL Neves, DP Petek, J Sawicka-Powierza, A Schneider, E Smyrnakis, S Streit, H Thulesius, P Vedsted and B Weltermann participated in the study design, piloting and data collection. G Taylor participated in the study design. S Harker coded some of the data. M Esteva and S Harker assisted in validated the coding. M Esteva, M Harris, R Hoffman, T Koskela, AL Neves, D Petek and H Thulesius worked together to agree the themes. M Harris had overall responsibility for the study design, recruitment of local leads, analysis of data and interpretation of results. All authors contributed to the writing and review of the manuscript and approved the final version.

## Acknowledgements

The authors would like to thank all the PCPs who piloted the questionnaire and those who completed the survey. They also thank the following non-author contributors: Isabelle Aubin-

1 Auger (Université Paris Diderot, Paris, France), Joseph Azuri (Tel Aviv University, Tel Aviv,  
2 Israel), Svjetlana Gašparović Babić (The Teaching Institute of Public Health of Primorsko-  
3 goranska County, Rijeka, Croatia) and Marija Petek Šter (University of Ljubljana, Ljubljana,  
4 Slovenia).  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only



## References

1. Møller H, Linklater KM, Robinson D. A visual summary of the EURO CARE-4 results: a UK perspective. *Br J Cancer* 2009;101(Suppl 2):S110-4.
2. EURO CARE. EURO CARE-5. In: Istituto Nazionale Tumori (Milan IaISdSR, Italy), ed. Milan and Rome, 2014.
3. Maringe C, Walters S, Rachet B, et al. Stage at diagnosis and colorectal cancer survival in six high-income countries: a population-based study of patients diagnosed during 2000-2007. *Acta Oncol* 2013;52(5):919-32. doi: 10.3109/0284186X.2013.764008. Epub 2013 Apr 15.
4. Walters S, Maringe C, Coleman MP, et al. Lung cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK: a population-based study, 2004-2007. *Thorax* 2013;68(6):551-64. doi: 10.1136/thoraxjnl-2012-202297 [published Online First: 2013/02/13]
5. Richards M. The size of the prize for earlier diagnosis of cancer in England. *Br J Cancer* 2009;101 Suppl 2:S125-S29. doi: 10.1038/sj.bjc.6605402
6. Woods LM, Coleman MP, Lawrence G, et al. Evidence against the proposition that "UK cancer survival statistics are misleading": simulation study with National Cancer Registry data. *BMJ* 2011;342:d3399.(doi):10.1136/bmj.d3399.
7. Zahl PH, Jorgensen KJ, Gotzsche PC. Overestimated lead times in cancer screening has led to substantial underestimation of overdiagnosis. *Br J Cancer* 2013;109(7):2014-9. doi: 10.1038/bjc.2013.427. Epub 13 Aug 20.
8. Carter JL, Coletti RJ, Harris RP. Quantifying and monitoring overdiagnosis in cancer screening: a systematic review of methods. *BMJ* 2015;350:g7773.(doi):10.1136/bmj.g7773.
9. Peto J. Cancer epidemiology in the last century and the next decade. *Nature* 2001;411(6835):390-5. doi: 10.1038/35077256 [published Online First: 2001/05/18]
10. Popic T, Schneider SM. An East-West comparison of healthcare evaluations in Europe: Do institutions matter? *J Eur Soc Policy* 2018;28(5):517-34. doi: 10.1177/0958928717754294
11. Boscoe FP, Henry KA, Sherman RL, et al. The relationship between cancer incidence, stage and poverty in the United States. *Int J Cancer* 2016;139(3):607-12. doi: 10.1002/ijc.30087
12. Schrijvers C, Mackenbach J, Lutz J-M, et al. Deprivation and survival from breast cancer. *Br J Cancer* 1995;72(3):738. doi: 10.1038/bjc.1995.403
13. Mackie RM, Hole DJ. Incidence and thickness of primary tumours and survival of patients with cutaneous malignant melanoma in relation to socioeconomic status. *BMJ* 1996;312(7039):1125. doi: 10.1136/bmj.312.7039.1125
14. Butler J, Foot C, Bomb M, et al. The International Cancer Benchmarking Partnership: An international collaboration to inform cancer policy in Australia, Canada, Denmark, Norway, Sweden and the United Kingdom. *Health Policy* 2013;112(1):148-55.
15. Green T, Atkin K, Macleod U. Cancer detection in primary care: insights from general practitioners. *Br J Cancer* 2015;112:S41. doi: 10.1038/bjc.2015.41

16. Jacobsen MM, Silverstein SC, Quinn M, et al. Timeliness of access to lung cancer diagnosis and treatment: A scoping literature review. *Lung Cancer* 2017;112:156-64. doi: 10.1016/j.lungcan.2017.08.011 [published Online First: 2017/12/02]
17. McLaughlin JM, Anderson RT, Ferketich AK, et al. Effect on survival of longer intervals between confirmed diagnosis and treatment initiation among low-income women with breast cancer. *J Clin Oncol* 2012;30(36):4493-500. doi: 10.1200/jco.2012.39.7695 [published Online First: 2012/11/22]
18. Yun YH, Kim YA, Min YH, et al. The influence of hospital volume and surgical treatment delay on long-term survival after cancer surgery. *Ann Oncol* 2012;23(10):2731-7. doi: 10.1093/annonc/mds101 [published Online First: 2012/05/04]
19. Gobbi PG, Bergonzi M, Comelli M, et al. The prognostic role of time to diagnosis and presenting symptoms in patients with pancreatic cancer. *Cancer Epidemiol* 2013;37(2):186-90. doi: 10.1016/j.canep.2012.12.002 [published Online First: 2013/02/02]
20. Tørring ML, Frydenberg M, Hansen RP, et al. Evidence of increasing mortality with longer diagnostic intervals for five common cancers: a cohort study in primary care. *Eur J Cancer* 2013;49(9):2187-98. doi: 10.1016/j.ejca.2013.01.025 [published Online First: 2013/03/05]
21. Elit LM, O'Leary EM, Pond GR, et al. Impact of wait times on survival for women with uterine cancer. *J Clin Oncol* 2014;32(1):27-33. doi: 10.1200/jco.2013.51.3671 [published Online First: 2013/11/28]
22. Nanthamongkolkul K, Hanprasertpong J. Longer waiting times for early stage cervical cancer patients undergoing radical hysterectomy are associated with diminished long-term overall survival. *J Gynecol Oncol* 2015;26(4):262-9. doi: 10.3802/jgo.2015.26.4.262 [published Online First: 2015/09/26]
23. Neal R, Tharmanathan P, France B, et al. Is increased time to diagnosis and treatment in symptomatic cancer associated with poorer outcomes? Systematic review. *Br J Cancer* 2015;112 Suppl 1:S92-S107. doi: 10.1038/bjc.2015.48 [published Online First: 2015/03/04]
24. Olsson JK, Schultz EM, Gould MK. Timeliness of care in patients with lung cancer: a systematic review. *Thorax* 2009;64(9):749-56. doi: 10.1136/thx.2008.109330
25. Malmström M, Rasmussen BH, Bernhardson B-M, et al. It is important that the process goes quickly, isn't it?" A qualitative multi-country study of colorectal or lung cancer patients' narratives of the timeliness of diagnosis and quality of care. *Eur J Oncol Nurs* 2018;34:82-88. doi: 10.1016/j.ejon.2018.04.002
26. Foot C, Harrison T. How to improve cancer survival: explaining England's relatively poor rates. London: The King's Fund, 2011:30 January 2012.
27. Harris M, Frey P, Esteva M, et al. How health system factors influence referral decisions in patients that may have cancer: European symposium report. *J Cancer Res Ther* 2016;4(1):7-10. doi: 10.14312/2052-4994.2016-2
28. Johansen M-L, Holtedahl KA, Rudebeck CE. A doctor close at hand: How GPs view their role in cancer care. *Scand J Prim Health Care* 2010;28(4):249-55. doi: 10.3109/02813432.2010.526792
29. Adams E, Boulton M, Rose P, et al. Views of cancer care reviews in primary care: a qualitative study. *Br J Gen Pract* 2011;61(585):e173-e82. doi: 10.3399/bjgp11X567108

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
30. Mitchell GK, Burridge LH, Colquist SP, et al. General Practitioners' perceptions of their role in cancer care and factors which influence this role. *Health Soc Care Community* 2012;20(6):607-16. doi: 10.1111/j.1365-2524.2012.01075.x [published Online First: 2012/07/19]
  31. Perkins N, Coleman A, Wright M, et al. The 'added value' GPs bring to commissioning: a qualitative study in primary care. *Br J Gen Pract* 2014;64(628):e728-34. doi: 10.3399/bjgp14X682321
  32. Green T, Atkin K, Macleod U. GPs' perceptions and experiences of public awareness campaigns for cancer: a qualitative enquiry. *Health Expect* 2016;19(2):377-87. doi: 10.1111/hex.12362
  33. Harris M, Taylor G, Örenäs Research Group. How health system factors affect primary care practitioners' decisions to refer patients for further investigation: protocol for a pan-European ecological study. *BMC Health Serv Res* 2018;18(1):338. doi: 10.1186/s12913-018-3170-2
  34. Center for Aging in Diverse Communities. Guidelines for Translating Surveys in Cross-Cultural Research. San Francisco: University of California, 2007.
  35. Maneesriwongul W, Dixon JK. Instrument translation process: a methods review. *J Adv Nurs* 2004;48(2):175-86. doi: 10.1111/j.1365-2648.2004.03185.x [published Online First: 2004/09/17]
  36. Harris M, Vedsted P, Esteva M, et al. Identifying important health system factors that influence primary care practitioners' referrals for cancer suspicion: a European cross-sectional survey. *BMJ Open* 2018;8(9) doi: 10.1136/bmjopen-2018-022904
  37. Patton M. Qualitative Research & Evaluation Methods. Beverly Hills, CA: Sage 1990:177.
  38. Braun V, Clarke V. Using thematic analysis in psychology. *Qual Res Psychol* 2006;3(2):77-101. doi: 10.1191/1478088706qp063oa
  39. Daly H, Collins C. Barriers to early diagnosis of cancer in primary care: a needs assessment of GPs. *Ir Med J* 2007;100(10):624-6. [published Online First: 2008/02/19]
  40. Car LT, Papachristou N, Urch C, et al. Preventing delayed diagnosis of cancer: clinicians' views on main problems and solutions. *Journal of global health* 2016;6(2):020901. doi: 10.7189/jogh.06.020901 [published Online First: 2016/12/29]
  41. Ersin F, Bahar Z. Barriers and facilitating factors perceived in Turkish women's behaviors towards early cervical cancer detection: a qualitative approach. *Asian Pacific journal of cancer prevention : APJCP* 2013;14(9):4977-82. [published Online First: 2013/11/02]
  42. Cassim S, Chepulis L, Keenan R, et al. Patient and carer perceived barriers to early presentation and diagnosis of lung cancer: a systematic review. *BMC Cancer* 2019;19(1):25. doi: 10.1186/s12885-018-5169-9 [published Online First: 2019/01/10]
  43. Kislov R, Walshe K, Harvey G. Managing boundaries in primary care service improvement: a developmental approach to communities of practice. *Implementation science : IS* 2012;7:97. doi: 10.1186/1748-5908-7-97 [published Online First: 2012/10/17]
  44. Cook N, Hart A, Nuttall K, et al. A telephone survey of cancer awareness among frontline staff: informing training needs. *Br J Cancer* 2011;105(3):340-45. doi: 10.1038/bjc.2011.258 [published Online First: 2011/07/12]
  45. Cook N, Thomson G, Dey P. Managing risk in cancer presentation, detection and referral: a qualitative study of primary care staff views. *BMJ Open* 2014;4(6) doi: 10.1136/bmjopen-2014-004820

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
46. Rubin G, Vedsted P, Emery J. Improving cancer outcomes: better access to diagnostics in primary care could be critical. *Br J Gen Pract* 2011;61(586):317-18. doi: 10.3399/bjgp11X572283
47. Rubin GP, Saunders CL, Abel GA, et al. Impact of investigations in general practice on timeliness of referral for patients subsequently diagnosed with cancer: analysis of national primary care audit data. *Br J Cancer* 2015;112(4):676-87. doi: 10.1038/bjc.2014.634
48. Jiwa M, Meng X, O'Shea C, et al. How do general practitioners manage patients with cancer symptoms? A video-vignette study. *BMJ Open* 2015;5(9) doi: 10.1136/bmjopen-2015-008525

**Table 1.** National distribution of PCPs who responded to the question 'How do you think the speed of diagnosis of cancer in primary care could be improved?'

Country	Number of PCPs who completed the survey	Number who answered the open-ended question (% of all survey completers)
Bulgaria	52	45 (86.5)
Croatia	56	42 (75.0)
Denmark	92	71 (77.2)
England	62	25 (40.3)
Finland	61	39 (63.9)
France	52	35 (67.3)
Germany	91	31 (34.1)
Greece	59	50 (84.7)
Israel	58	42 (72.4)
Italy	60	52 (86.7)
Netherlands	108	84 (77.8)
Norway	81	46 (56.8)
Poland	135	103 (76.3)
Portugal	59	46 (78.0)
Romania	146	132 (90.4)
Scotland	62	55 (88.7)

Slovenia	91	52 (57.1)
Spain	380	332 (87.4)
Sweden	68	55 (80.9)
Switzerland	60	15 (25.0)
Total	1,833	1,352 (73.8)

For peer review only

**Table 2.** Demographic distribution of PCPs who responded to the question ‘How do you think the speed of diagnosis of cancer in primary care could be improved?’

Demographic	Number (%)
Gender	
Female	833 (61.6)
Male	513 (38.0)
Not stated	5 (0.4)
Years since graduation	
<10	192 (14.2)
10–19	356 (26.4)
20–29	416 (30.8)
30–39	336 (24.9)
40 or over	47 (3.5)
Not stated	4 (0.3)
Site of practice	
Urban	816 (60.4)
Rural	314 (23.2)
Island	25 (1.9)

Mixed	194 (14.4)
Not stated	2 (0.1)
Number of doctors in practice	
1-2	337 (24.9)
3-5	344 (25.5)
6-9	290 (21.5)
10 or more	374 (27.7)
Not stated	6 (0.4)

For peer review only



## Figure legends

**Figure 1.** *Diagrammatic representation of themes emerging from responses to the question:*  
*'How do you think the speed of diagnosis of cancer in primary care could be improved?'*

For peer review only




Figure 1. Diagrammatic representation of themes emerging from responses to the question: 'How do you think the speed of diagnosis of cancer in primary care could be improved?'

292x200mm (300 x 300 DPI)

## Supplementary file. Ethical and other approvals obtained in each Örenäs Research Group participating jurisdiction

	Date of Ethics Approval	Approvals obtained	Reference
Bulgaria	29 October 2015	Medical University Plovdiv Ethical Commission	P-7820
Croatia	16 December 2016	Nastavni Zovod Za Javno Zdravstvo	08-820-61/31-15
Denmark	7 May 2016	Danish Data Protection Agency; according to Danish law and the Central Denmark Region Committees on Health Research Ethics, approval by the National Committee on Health Research Ethics was not required as no biomedical intervention was performed.	2009-41-3471
Finland	16 November 2016	Academic Ethics Committee of the Tampere Region	16 November 2016
France	N/A	In France, research ethics approval was not required as no biomedical intervention was performed.	
Germany	15 January 2016	Ethik-Kommission Universität Duisberg-Essen	16-6747-BO
Greece	N/A	In Greece, research ethics approval was not required as no biomedical intervention was performed.	
Israel	N/A	In Israel, research ethics approval was not required as no biomedical intervention was performed.	
Italy	N/A	In Italy the approval of the ethical committee is not required when a study is neither an interventional nor an observational study on pharmacological treatment.	Decreto Legislativo n. 211 (24 giugno 2003)<2001/20/EC
Netherlands	27 June 2016	medisch-ethischetoetsingscommissie (METC) azM/UM Maastricht UMC+	METC 16-4-113
Norway	N/A	In Norway, research ethics approval was not required as no biomedical intervention was performed.	
Poland	28 January 2016	Komisja Bioetyczna Uniwersytetu Medycznego w Białymstoku	R_I_022/10/2016

1 2 3	Portugal	N/A	In Portugal, research ethics approval was not required as no biomedical intervention was performed.	
4 5 6 7	Romania	N/A	In Romania, research ethics approval was not required as no biomedical intervention was performed.	
8 9	Slovenia	8 December 2014	Komisija Republike Slovenije Medicinsko Etiko	KME 113/08/14
10 11 12 13 14 15 16	Spain	25 October 2015 23 Decmber 2015	Comissio d'Investigacio Govern de les Illes Balears Informe del Comite Etic d'Investigacio Clinica	Palma 27oct15 P15/159
17 18 19 20 21 22 23 24	Sweden	N/A	In Sweden, research ethics approval was not required as no biomedical intervention was performed. It does not fall under the law of research on human subjects to ask professionals about their work and how they perceive it.	
25 26 27 28 29 30 31	Switzerland	N/A	Swiss law on human research (Humanforschungsgesetz, HFG) does not require that an ethics committee approve collection and analysis of non-medical and anonymous data.	
32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60	United Kingdom	24 November 2014	Research Ethics Approval Committee for Health, University of Bath	EP 14/15 66

# Reporting checklist for qualitative study.

Based on the SRQR guidelines.

## Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the SRQR reporting guidelines, and cite them as:

O'Brien BC, Harris IB, Beckman TJ, Reed DA, Cook DA. Standards for reporting qualitative research: a synthesis of recommendations. *Acad Med.* 2014;89(9):1245-1251.

	Reporting Item	Page Number
	<a href="#">#1</a> Concise description of the nature and topic of the study identifying the study as qualitative or indicating the approach (e.g. ethnography, grounded theory) or data collection methods (e.g. interview, focus group) is recommended	1
	<a href="#">#2</a> Summary of the key elements of the study using the abstract format of the intended publication; typically includes background, purpose, methods, results and conclusions	4-5
Problem formulation	<a href="#">#3</a> Description and significance of the problem / phenomenon studied: review of relevant theory and empirical work; problem statement	7-8
Purpose or research question	<a href="#">#4</a> Purpose of the study and specific objectives or questions	8
Qualitative approach and research paradigm	<a href="#">#5</a> Qualitative approach (e.g. ethnography, grounded theory, case study, phenomenology, narrative research) and guiding theory if appropriate; identifying the research paradigm (e.g. postpositivist, constructivist / interpretivist) is also	10-11

recommended; rationale. The rationale should briefly discuss the justification for choosing that theory, approach, method or technique rather than other options available; the assumptions and limitations implicit in those choices and how those choices influence study conclusions and transferability. As appropriate the rationale for several items might be discussed together.

1			
2			
3			
4			
5			
6			
7			
8			
9			
10	Researcher characteristics	<a href="#">#6</a>	11
11	and reflexivity	Researchers' characteristics that may influence the research, including personal attributes, qualifications / experience, relationship with participants, assumptions and / or presuppositions; potential or actual interaction between researchers' characteristics and the research questions, approach, methods, results and / or transferability	
12			
13			
14			
15			
16			
17			
18			
19			
20	Context	<a href="#">#7</a>	10
21		Setting / site and salient contextual factors; rationale	
22	Sampling strategy	<a href="#">#8</a>	10
23		How and why research participants, documents, or events were selected; criteria for deciding when no further sampling was necessary (e.g. sampling saturation); rationale	
24			
25			
26			
27	Ethical issues pertaining	<a href="#">#9</a>	10; 24
28	to human subjects	Documentation of approval by an appropriate ethics review board and participant consent, or explanation for lack thereof; other confidentiality and data security issues	
29			
30			
31			
32			
33	Data collection methods	<a href="#">#10</a>	9
34		Types of data collected; details of data collection procedures including (as appropriate) start and stop dates of data collection and analysis, iterative process, triangulation of sources / methods, and modification of procedures in response to evolving study findings; rationale	
35			
36			
37			
38			
39			
40			
41	Data collection	<a href="#">#11</a>	9
42	instruments and	Description of instruments (e.g. interview guides, questionnaires) and devices (e.g. audio recorders) used for data collection; if / how the instruments(s) changed over the course of the study	
43	technologies		
44			
45			
46			
47			
48	Units of study	<a href="#">#12</a>	11
49		Number and relevant characteristics of participants, documents, or events included in the study; level of participation (could be reported in results)	
50			
51			
52			
53	Data processing	<a href="#">#13</a>	10
54		Methods for processing data prior to and during analysis, including transcription, data entry, data management and security, verification of data integrity, data coding, and anonymisation / deidentification of excerpts	
55			
56			
57			
58			
59			
60			

1	Data analysis	<a href="#">#14</a>	Process by which inferences, themes, etc. were identified and developed, including the researchers involved in data analysis; usually references a specific paradigm or approach; rationale	10
2				
3				
4				
5				
6	Techniques to enhance trustworthiness	<a href="#">#15</a>	Techniques to enhance trustworthiness and credibility of data analysis (e.g. member checking, audit trail, triangulation); rationale	10-11
7				
8				
9				
10				
11	Syntheses and interpretation	<a href="#">#16</a>	Main findings (e.g. interpretations, inferences, and themes); might include development of a theory or model, or integration with prior research or theory	11-19
12				
13				
14				
15				
16				
17	Links to empirical data	<a href="#">#17</a>	Evidence (e.g. quotes, field notes, text excerpts, photographs) to substantiate analytic findings	11-19
18				
19				
20				
21	Intergration with prior work, implications, transferability and contribution(s) to the field	<a href="#">#18</a>	Short summary of main findings; explanation of how findings and conclusions connect to, support, elaborate on, or challenge conclusions of earlier scholarship; discussion of scope of application / generalizability; identification of unique contributions(s) to scholarship in a discipline or field	20-23
22				
23				
24				
25				
26				
27				
28				
29	Limitations	<a href="#">#19</a>	Trustworthiness and limitations of findings	20-21
30				
31	Conflicts of interest	<a href="#">#20</a>	Potential sources of influence of perceived influence on study conduct and conclusions; how these were managed	25
32				
33				
34				
35	Funding	<a href="#">#21</a>	Sources of funding and other support; role of funders in data collection, interpretation and reporting	25
36				
37				
38				

39 The SRQR checklist is distributed with permission of Wolters Kluwer © 2014 by the Association of American  
 40 Medical Colleges. This checklist can be completed online using <https://www.goodreports.org/>, a tool made by  
 41 the [EQUATOR Network](#) in collaboration with [Penelope.ai](#)  
 42  
 43  
 44  
 45  
 46  
 47  
 48  
 49  
 50  
 51  
 52  
 53  
 54  
 55  
 56  
 57  
 58  
 59  
 60